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1. DRUG DELIVERY SYSTEM 
The Drug delivery system refers to a system for transporting pharmaceutical compound 
in the body to provide a desired and required therapeutic effect. Drug delivery is a concept 
integrated with dosage form and route of administration of pharmaceutical products. The 
technologies involved in the formulation of pharmaceutical products modify drug release profile, 
absorption, distribution and elimination for the benefit of improving product efficacy and safety, 
as well as patient convenience and compliance. Drug release is from: diffusion, degradation, 
swelling, and affinity-based mechanisms. Most common routes of administration are non-
invasive peroral (through the mouth), topical (skin), transmucosal (nasal, buccal/sublingual, 
vaginal, ocular and rectal) and inhalation routes.
1
 
Newer development of pharmaceutical compounds in the form of  targeted delivery 
system, in which the drug is only active in the target area of the body (for example, in cancerous 
tissues, in brain, in colon), sustained release formulations in which the drug is released over a 
period of time in a controlled manner from a formulation.
1  
 
2. NOVEL DRUG DELIVERY SYSTEM 
The aim of  Novel Drug Delivery  System is to provide a therapeutic amount of drug to 
the appropriate site in the body to  accomplish promptly and then maintain  the  desired drug   
concentration. The drug-delivery system should deliver drug at a rate control by  the necessarily 
of  the body over a specified  term of treatment.
2 
This idealized objectives witch to the two aspects most important to drug delivery areas 
follows,
2
 
I.     Spatial Drug Delivery: 
Targeting a drug to a particular organ or tissue. 
 
II.     Temporal Drug Delivery: 
 
The drug delivery rate to the target tissue is controlled. 
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The prime area so research and development for NDDS are:  
 Liposomes 
Niosomes 
Nanoparticles 
Transdermaldrugdelivery 
Implants 
Oralsystem 
Microencapsulation/Microcapsules 
Polymer in drug delivery 
 
 
 
Figure-1 :Polymers used in Drug Delivery system. 
 
Efficacy of a drug can be altered by the method of drug delivery into the body. Some 
drugs has an optimum concentration in the body and produce maximum therapeutic level, 
concentration above or below can produce toxic or no therapeutic action. Slow efficacy of drug 
in severe diseases has increases the need for a multidisciplinary approach to the delivery of 
therapeutics to targets in tissues. To solve this problem newer development of pharmaceutical 
compounds were generated to controlling the pharmacokinetics, pharmacodynamics, non-
specific toxicity, immunogenicity, bio recognition, and efficacy of drugs. The drug delivery 
systems (DDS), based on interdisciplinary approaches that combine polymer science, 
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pharmaceutics, bioconjugate chemistry, and molecular biology are called as Novel drug delivery 
system (NDDS).
3 
 To minimize drug degradation and loss, to prevent harmful side-effects and to increase 
drug bioavailability and the fraction of the drug accumulated in the required zone, various drug 
delivery and drug targeting systems are currently under development. Drug carriers  can named 
as  soluble polymers, microparticles made of insoluble or biodegradable natural and synthetic 
polymers, microcapsules, cells, cell ghosts, lipoproteins, liposomes, and micelles. The carriers 
can be made slowly degradable, stimuli-reactive (e.g., pH- or temperature-sensitive), and even 
targeted (e.g., by conjugating them with specific antibodies against certain characteristic 
components of the area of interest).
3 
ADVANTAGES OF NOVEL DRUG DELIVERY SYSTEM
4  
 Minimization of drug degradation and loss. 
 Reduction of dosing frequency. 
 Extension of the duration of action and bioavailability of the drug. 
 Prevention of drug’s adverse side-effects. 
 Minimization of drug concentration fluctuations in plasma level. 
 Improved drug utilization. 
 Improved patient compliance. 
DISADVANTAGES OF NOVEL DRUG DELIVERY SYSTEM
4 
 High cost of final product. 
 Patients discomfort with DDS device usage. 
 Possibility of toxicity of the materials. 
 Harmful degradation products. 
 Necessity of surgical intervention either on systems application or removal. 
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CLASSIFICATION OF DRUG DELIVERY SYSTEM:
5 
 
Classification of NDDS based on Physical means 
1) Osmotic Pressure Activated 
2) Hydrodynamic pressure activated 
3) Vapor pressure activated 
4) Mechanically activated 
5) Magnetically activated 
6) Sonophoresis 
7) Iontophoresis 
8) Hydration activated 
Classification of NDDS based on Chemical means 
1) Hydrolysis activated 
2) Ion activated 
3) pH activated 
 
Targeting the drug to a specific site by two mechanisms that is (i) Active Targeting and (ii) 
passive Targeting.
6 
Potential release mechanism
6 
involves (i) Desorption of surface -bound or adsorbed drugs, (ii) 
diffusion through the carrier matrix, (iii) diffusion through the carrier wall(in case of 
nanocapsules),(iv) carrier matrix erosion, and (v) a combined erosion /diffusion process. 
Sustained (or) continuous release
6
 of a drug involves polymers that release the drug at a 
controlled rate due to diffusion out of the polymer or by degradation of the polymer over time. 
Pulsatile release
6
 is often the preferred method of drug delivery, as it closely mimics the way by 
which the body naturally produce hormones such as insulin. 
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Colloidal drug carrier system
6
 such as micellar solution, vesicle and liquid crystal dispersion as 
well as nanoparticle consisting of small particles of 10-400 nm diameter shows great promise as 
drug delivery system. 
Micelles
6
 formed by self - assembly of amphiphilic block co-polymer (5-50 nm) in aqueous 
solutions are of great interest for drug delivery application. They can be physically entrapped in 
the core of block copolymer micelles and transported at concentration that can exceed their 
intrinsic water solubility. 
Liposomes
3
 are a form of vesicles that consist either of many, few or just one phospholipid 
bilayers. The polar character of the liposomal core enables polar drug molecules to be 
encapsulated. Amphiphilic and lipophilic molecules are solubilized within the phospholipid 
bilayer according to their affinity towards the phospholipids. Participation of nonionic 
surfactants instead of phospholipids in the bilayer formation results inniosomes. The drugs that 
are encapsulated in a nanocage-functionalized with channel proteins are effectively protected 
from premature degradation by proteolytic enzymes. 
Dendrimers
3
 are nanometer-sized, highly branched and monodisperse macromolecules with 
symmetrical architecture. They consist of a central core, branching units and terminal functional 
groups. The core together with the internal units, determine the environment of the nanocavities 
and consequently their solubilizing properties, whereas the external groups the solubility and 
chemical behaviour of these polymers. 
Liquid Crystals
3 
combine the properties of both liquid and solid states. They can be made to 
form different geometries, with alternative polar and non-polar layers (i.e., a lamellar phase) 
where aqueous drug solutions can be included. 
Nanoparticles
7
  can be defined as particulate dispersion or  solid particle with a size range in 10-
1000 nm.The drug is dissolved , entrapped, encapsulate or attached to a nanoparticle matrix. 
Depending upon the method of preparations, nanoparticle, nanospheres, or nanocapsules can be 
obtained. 
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The primary goals for research of nano-bio-technologies in drug delivery include:
8
 
 More specific drug targeting and delivery, 
 Reduction in toxicity while maintaining therapeutic effects, 
 Greater safety and biocompatibility, and 
 Faster development of new safe medicines. 
 
Method of preparation:
 
1. Dispersion of preformed polymers.9 
a) Solvent evaporation method.11 
b) Spontaneous emulsification or solvent diffusion method.11 
2. Polymerization of monomers9 and 
3. Ionic gelation  or coacervation of hydrophilic polymers.9 
4. Supercriticalfluid technology.11 
1.Dispersion of preformed polymers:
11 
 It is the most common method used to prepare nanoparticle from poly(lactic acid) (PLA), 
poly (D L Glycolide), PLG, Poly(D,L-lactide-co-glycolide) PLGA, and Poly(cyanoacrylates) 
PCA. 
a) Solvent evaporation method:11 
Organic solvent such as Dichloromethane, Chloroform, or ethyl acetate are used to 
dissolve the polymer which is also used as solvent to dissolve  hydrophobicdrugs. The 
drug dissolved or dispersed in a polymer solution is then emulsified in an aqueous 
solution containing a surfactant or emulsifying agent to form oil in water emulsion. Once 
a stable emulsion is formed the solvent is subjected to evaporation either by reducing the 
pressure or by continuous stirring. High speed homogenizer or Ultra sonicator is used for 
the preparation of small uniform sized particle. 
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b) Spontaneous emulsification or solvent diffusion method:11 
This is a modification of solvent evaporation method. In this the water miscible solvent 
along with water immiscible organic solvent is used as an oil phase. An interfacial 
turbulence is formed between the two phases due to spontaneous diffusion of immiscible 
solvents leading to formation of small particles. By increasing the concentration of water 
miscible solvent decrease in the particle size can be achieved. Both solvent evaporation 
and solvent diffusion methods can be used for the hydrophobic and hydrophilic drugs.  
 2.Polymerization of monomers:
11 
In this method monomers are polymerized to form nanoparticle in an aqueous solution in which 
drug maybe dissolved. Drugs may also be incorporated by adsorption onto the nanoparticles after 
polymerization completed.   The nanoparticle suspension is then purified by ultracentrifugation 
and resuspending in an isotonic surfactant - free medium. This technique is used for preparing 
polybutylcyanoacrylateor poly (alkylcyanoacrylate) nanoparticle. 
3.Ionic gelation  or coacervation of hydrophilic polymers :  
 The method involves a mixture of two aqueous phases, of which one is the polymer 
chitosan, a di-block co-polymer ethylene oxide or propylene oxide (PEO or PPO) and the other is 
the polyanion sodium tripolyphospate. Positively charged amino group in chitosan interacts with 
negatively charged tripolyphosphate to form coacervates with a size in the range of nanometer. 
Coacervates are formed as a result of electrostatic interaction between two phases , whereas, 
ionic gelation involves the material undergoing transition from liquid to gel due to ionic 
interaction condition  at room temperature. 
4.Supercritical fluid technology: 
         Supercritical fluid technology has been investigated as an alternative to prepare 
biodegradable micro and nanoparticles. Supercritical fluids are environmentally safe. 
A supercritical fluid can be generally defined as a solvent at a temperature above its 
critical temperature, at which the fluid remains a single phase regardless of pressure. 
Supercritical CO2(SCCO2)is the most widely used supercritical fluid because of its mild critical 
conditions (Tc=31.1°C,Pc=73.8bars),non toxicity, non-flammability, and lowprice. The most 
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common processing techniques involving supercritical fluids are supercritical anti- solvent(SAS) 
and rapid expansion of critical solution (RESS).  
 Nanoparticle 
10
can be formulated, as injections consisting of spherical amorphous 
particles which do not aggregate, hence they can be safely administered by the intravenous route. 
Since no cosolvent is used to solubilize the drug, the overall toxicity of the formulation is 
decreased. 
Nanoparticles represent very promising carrier system for the targeting of anti-cancer 
agents to tumors. Nanoparticles exhibit a significant tendency to accumulate in a number of 
tumors after iv injection. Nanoparticles can also be used in Brain Drug Targeting. Poly (butyl 
cyanoacrylate) nanoparticles represent the only nanoparticles that were so far successfully used 
for in vivo delivery of drugs to brain. This polymer has the advantage that it is very rapidly 
biodegradable. The first drug that was delivered to brain using nanoparticles was the 
Hexapeptide Dalargin (Tyr-D-Ala-Gly-Phe-Leu-Arg), a Leu-enkephalin analouge with opioid 
activity. Other drugs that have successfully been transported into the brain are loperamide, 
tubocurarine, and doxorubicin. Nanoparticles mediated drug transport to the brain depends on the 
over coating of the particles with polysorbates, especially polysorbate 80.  
 
 Figure-2 :(a, b, and c) images of prepared mesoporous silica nanoparticles with mean outer 
diameter: (a) 20nm, (b) 45nm, and (c) 80nm. (d) image corresponding to (b). The insets are a hig 
magnification of mesoporous silica particle. 
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TYPES OF NANOPARTICLES 
1. Quantum Dot 
Aquantum dot is a semiconductor nanostructure that confines the motion of conduction 
band electrons, valence band holes, or excitons (pairs of conduction band electrons and 
valence band holes) in all three spatial directions. The confinement can be due to 
electrostatic potentials (generated by external electrodes, doping, strain, impurities), due 
to the presence of an interface between different semiconductor materials (e.g. in the case 
of self-assembled quantum dots), due to the presence of the semiconductor surface (e.g. 
in the case of a semiconductor nanocrystal), or to a combination of these. A quantum dot 
has a discrete quantized energy spectrum. A quantum dot contains a small integer number 
(of the order of 1-100) of conduction band electrons, valence band holes, or excitons, i.e., 
an integer number of elementary electric charges. 
Quantum dots can be contrasted to other semiconductor nanostructures: 
1) Quantum wires, which confine the motion of electrons or holes in two spatial 
directions and allow free propagation in the third. 
2) Quantum wells, which confine the motion of electrons or holes in one direction and 
allow free propagation in two directions. 
2. Nanocrystalline silicon 
Nanocrystallinesilicon(nc-Si) - an allotropic form of silicon - is similar to amorphous 
silicon (a-Si), in that it has an amorphous phase. Where they differ, however, is that nc-Si 
has small grains of crystalline silicon within the amorphous phase. This is in contrast to 
polycrystalline silicon (poly-Si) which consists solely of crystalline silicon grains, 
separated by grain boundaries. nc-Si is sometimes also known as microcrystalline 
silicon (µc-Si) The difference comes solely from the grain size of the crystalline grains. 
Most materials with grains in the micrometre range are actually fine- grained polysilicon, 
so nanocrystalline silicon is a better term. 
3. Photonic crystal 
Photonic crystals are periodic dielectric or metallo-dielectric (nano) structures that are 
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designed to affect the propagation of electromagnetic waves (EM) in the same way as the 
periodic potential in a semiconductor crystal affects the electron motion by defining 
allowed and forbidden electronic energy bands. 
Since the basic physical phenomenon is based on diffraction, the periodicity of the photonic 
crystal structure has to be in the same length-scale as half the wavelength of the EM 
waves i.e. ~300 nm for photonic crystals operating in the visible part of the spectrum. 
This makes the synthesis cumbersome and complex. To circumvent nanotechnological 
methods with their big and complex machinery, different approaches have been followed 
to grow photonic crystals as self-assembled structures from colloidal crystals. 
Photonic crystals are attractive optical materials for controlling and manipulating the flow of 
light. They are of great interest for both fundamental and applied research, and are 
expected to find commercial applications soon. 
 
 
                        Figure-3:      STRUCTURE OF NANOPARTICLES 
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4. Liposomes 
A liposome is a spherical vesicle with a membrane composed of a phospholipid bilayer used to 
deliver drugs or genetic material into a cell. Liposomes can be composed of naturally-derived 
phospholipids with mixed lipid chains (like egg, phosphatidyl ethanolamine), or of pure 
components like DOPE (di oleolyl phosphatidyl ethanolamine). 
The lipid bilayer can fuse with other bilayers (e.g., the cell membrane), thus delivering the 
liposome contents. By making liposomes in a solution of DNA or drugs,(which would 
normally be unable to diffuse through the membrane), they can be (indiscriminately) 
delivered past the lipid bilayer. 
5. Gliadin nanoparticles 
In an effort to improve bioavailability anti-H.pylori effects of antibiotics, mucoadhesive 
gliadin  nanoparticles (GNP) which have the ability to deliver the antibiotics at the sites 
of infection were prepared. GNP bearing clarithromycin(CGNP) and omeprazole(OGNP) 
were prepared by desolvation method. 
in vivo gastric mucoadhesive studies confirmed the strong mucoadhesive propensity and 
specificity and specificity of gliadin nanoparticles towards stomach. Gliadin nanoparticles 
show a higher tropism for the gastrointestinal regions and their presence in other intestinal 
regions is very low. This high capacity to interact with the mucosa may be explained by 
gliadin composition. 
In fact, this protein is rich in neutral and lipophilic residues. Neutral amino acid can promote 
hydrogen bonding interaction with the mucosa whereas the lipophilic components can 
interact within biological tissue by hydrophilic interaction. The related protein gliadin 
possessing an amino and disulphide groups on the side chain has a good probability of 
developing bonds with mucin gel. 
6. Polymeric Nanoparticles 
Polymeric nanoparticles have been invented by Speiser et al. They represent interesting 
alternative as drug delivery systems to liposomes. They usually exhibit a long shelf life 
and a good stability on storage. 
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These are superior to liposomes in targeting them to specific organs or tissues by adsorbing and 
coating their surface with different substances. 
Nanoparticles can be prepared either from preformed polymers, such as polyesters (i.e. 
polylactic acid), or from a monomer during its polymerization, as in the case of alkyl-
cyanoacrylates. 
Most of the methods based on the polymerization of monomers consists in adding a 
monomer into the dispersed phase of an emulsion, an inverse microemulsion, or dissolved 
in a non-solvent of the polymer. 
7. Solid Lipid Nanoparticles (SLN) 
Solid lipid nanoparticles have been developed as alternative delivery system to 
conventional polymeric nanoparticles. SLNs are sub-micron colloidal carriers (50-
1000nm) which are composed of physiological lipid, dispersed in water or in an aqueous 
surfactant solution. 
SLNs combine advantages of polymeric nanoparticles, fat emulsions and liposomes, but 
avoid some of their disadvantages. They are biodegradable, biocompatible and non-toxic. 
 8. Nanospheres
16 
Nanospheres may be defined as solid core spherical particulates, which are nano in size. 
They contain drug embedded within the matrix or adsorbed on to the surface. 
 
 9.  Nanocapsules
16 
 
Nanocapsules are the vesicular system  in  which  drug  is  essentially encapsulated 
within central volume surrounded by an embryonic continuous polymeric sheath. 
10. Others
10
: 
Gold nanoparticles stabilized by thiol functionality are extraordinarily stable and therefore are a 
great system for studying nanostructure formation. They have many applications. Because gold 
nanoparticles are so easy to synthesize they have been studied intensely in recent years. 
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A common synthesis involves the reduction of a gold salt in the presence of capping agent 
molecules such as thiols, citrates or phosphines. The functionalities of these capping 
agents can be altered to yield various chemical properties. 
Advantages of Nanoparticles 
 
Some of the advantages of using nanoparticles as a drug delivery system are as follows; 
1. Ease of manipulation of the particle size and surface characteristics of 
nanoparticles so as to achieve both passive and active drug targeting after parenteral 
administration. 
2. The nanoparticle surface can be modified to alter bio distribution of drugs with 
subsequent clearance of the drug so as to achieve maximum therapeutic efficacy with 
minimal side effects of the drug. 
3. Controlled release and particle degradation characteristics can be readily 
modulated by the choice of matrix constituents. 
4. Drug loading is relatively high and drugs can be incorporated into the systems 
without any chemical reaction; this is an important factor for preserving the drug 
activity. 
5. Site-specific targeting can be achieved by attaching targeting ligands to surface 
of particles or use of magnetic guidance. 
6. Liposomes and polymer based nanoparticulates are generally biodegradable, do 
not accumulate in the body and so are possibly risk free. 
7. Small sized nanoparticles can penetrate through smaller capillaries, which could 
allow efficient drug accumulation at the target sites. 
8. Various routes of administration are including oral, nasal, parenteral, intra-
ocular etc. 
 
Disadvantages 
 
In spite of these advantages nanoparticles do have limitations like, 
1. Altered physical properties which lead to particle–particle aggregation, making physical 
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handling  of nanoparticles difficult in liquid and dry forms due to smaller size and larger 
surface area. 
2. Smaller the particles size greater the surface area and this property makes nanoparticles very 
reactive in the cellular environment. 
3. Small particles size results in limited drug loading and burst release. These practical 
problems have to be sorted out before nanoparticles can be used clinically or made 
commercially available. 
 
ApplicationsofNanoparticles
12 
In Anti-Microbial Techniques : 
 One of the earliest  nanomedicine applications was the use of nanocrystalline silver 
which is  as an antimicrobial agent for the treatment of wounds, a nanoparticle cream has been 
shown to fight  infections. 
In Tumor targeting using :
 
The rational of using nanoparticles for tumor targeting is based on (1) nanoparticles will 
be able to deliver a concentrate dose of drug in the vicinity of  the tumor targets via the enhanced 
permeability and retention effect or active nanoparticles. (2) Nanoparticles will reduce the drug 
exposure of health tissues by limiting drug distribution to target organ. 
In Gene delivery : 
 Polynucleotide   vaccines  work  by  delivering genes encoding relevant antigens to host 
cells where they are expressed, producing the antigenic protein within the  vicinity of 
professional antigen presenting cells to initiate immune response. Such vaccines produce both 
humoral and cell-mediated immunity because intracellular production of protein, as opposed to 
extracellular deposition, stimulates both arms of the immune system. 
In Cell Repair : 
Nanorobots could actually be programmed to repair specific diseased cells, functioning 
in a similar way to antibodies in our natural healing processes. 
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In brain targeting : 
The blood-brain barrier(BBB)is the most important factor limiting the development of 
new drugs for the central nervous system. Relatively impermeable endothelial cells characterize 
the BBB with tight junctions, enzymatic activity and active efflux transport systems. It 
effectively prevents the passage of water-soluble molecules from the blood circulation into the 
CNS, and canal so reduce the brain concentration of lipid- soluble molecules by  the function of 
enzymes or efflux pumps. Consequently, the BBB only permits selective transport of molecules 
that are essential  for brain function. Strategies for nanoparticle targeting to the brain rely on the 
presence of and nanoparticle interaction with specific receptor- mediated transport systems in the 
BBB.
7 
Nanoparticles can get access to the brain by two different mechanisms, ie, (1) trans 
synaptic transport after inhalation through the olfactory epithelium, and (2) uptake through the 
blood-brain barrier.
8
 
 In some cases it is reported to mimic molecules that would normally be transported to 
brain. For example, polysorbate-coated nanoparticles are thought to mimic low-density 
lipoprotein (LDL), allowing them to be transported across the capillary wall and into the 
brain by hitching a ride on the LDL receptor.
13 
In Topical  drug delivery: 
Nanoemulgel
15
: 
When nanoemulsion is incorporated into gel it is called as nanoemul gel. Nanoemulsions 
are thermodynamically stable transparent (translucent)dispersions of oil and water stabilized by 
an interfacial film of surfactant and cosurfactant molecules having a droplet size of less 
than100nm. Nanoemulsion formulations possess improved transdermal and dermal delivery 
properties in-vitro as well as in-vivo. Nanoemulsions have improved transdermal permeation of 
many drugs over the conventional topical formulations such as emulsions and gels e.g.Carvedilol 
nanoemul gel was prepared using oleicacid and isopropyl myristate (3:1) as oil phase. Tween20 
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and Carbitol were used as surfactant and cosurfactant respectively. Carbopol934 was used as 
gelling agent
15
. 
Nanosponge:
17,18 
 Nanosponges are tiny mesh – like nanoporous particular structure in which a large variety 
of substances can be encapsulated or suspended, and then be incorporated into a dosage form. 
They have a proven spherical colloidal nature, reported to have a very high solubilization 
capacity for poorly soluble drugs by their inclusion and non-inclusion behavior. Nanosponges 
have recently been developed and proposed for drug delivery. Nanosponges can solubilize 
poorly water soluble drug and provide prolonged release as well as improving drugs 
bioavailability. Nanosponges are able to load both hydrophilic and hydrophobic drug molecules 
because of their inner hydrophobic cavities and external hydrophilic branching, thereby offering 
unparalleled flexibility .Nanosponges  are more like a three- dimensional network or scaffold. 
The backbone is a long length of polyester which is mixed in solution with small molecules 
called crosslinkers that act like tiny grappling hooks to fasten different parts of the polymer 
together. 
 
Figure-4 :  STRUCTURE OF NANOSPONGE 
Advantages of Nanosponge:
18,42 
    1.Targeted site specific drug delivery. 
2. Can be used to mask unpleasant flavours and to convert liquid substances to solids. 
INTRODUCTION 
 
Department of Pharmaceutics, Madras Medical college Page 17 
 
3. Less harmful side effects (since smaller quantities of the drug have contact with healthy 
tissue). 
4.Nanosponge particles are soluble in water, so the hydrophobic drugs can been capsulated 
with in the nanosponge, after mixing with a chemical called an adjuvant reagent. 
5. Particles can be made smaller or larger by varying the proportion of cross-linkerto the 
polymer. 
6.  Production through fairly simple chemistry called "click chemistry"(methods for making 
the Nanosponge particles and for attaching the linkers). 
7. Easy scale-up for commercial production. 
8.The drug profiles can be tailored from fast, medium to slow release, preventing over or 
under-dosing of the therapy. 
9.The material used in this system can provide a protective barrier that shields the drug from 
premature destruction with in the body. 
10.Improved stability, increased elegance and enhanced formulation flexibility. 
11.Nanosponges systems are non-irritating , non-mutagenic, non-allergenic and non-toxic. 
12.These are self sterilizing as the average pore sizeis 0.25µm, where bacteria cannot 
penetrate. 
13.Hydrophobic drugs can be encapsulated within the Nanosponge. 
14.Extended release-continuous action up to 12 h. 
15.Biodegradable. 
Disadvantages 
 
1. The main disadvantage of these nanosponges is their ability to include only small 
molecules. 
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2. The nanosponges could be either Para crystalline or in crystalline form. The loading 
capacity of nanosponges depends mainly on degree of crystallization. Para crystalline 
nanosponges can show different loading capacities. 
3.  The nanosponges can be synthesized to be of specific size and to release drugs overtime 
by varying the proportion of cross linker to polymer. 
Characteristic features of nanosponges
56
. 
 Nanosponges exhibit a range of dimensions (1 µm or less) with tunable polarity of the 
cavities. Nanosponges of specific size and adjustable polarity can be synthesized by 
varying the crosslinker to polymer proportion. 
 They could be either para-crystalline or in crystalline form, depending on the process 
conditions. Crystal structure of nanosponges plays a very important role in their 
complexation with drugs. 
 The drug loading capacity of nanosponges mainly depends on the degree of 
crystallization. Para-crystalline nanosponges have shown various drug loading capacities. 
 They are nontoxic, porous particles insoluble in most organic solvents and stable at high 
temperatures up to 300 °C. 
 Nanosponges as formulations are stable over the pH range of 1 to 11 and temperature up 
to 130 °C. 
 They form clear and opalescent suspensions in water and can be regenerated by simple 
thermal desorption, extraction with solvents, by the use of microwaves and ultrasounds. 
 Their 3D structure enables capture, transportation and selective release of a vast variety 
of substances. They can be targeted to different sites due to their ability to be linked with 
different functional groups. Chemical linkers enable nanosponges to bind preferentially 
to the target site. They form inclusion and non-inclusion complexes with different drugs. 
 Magnetic properties can be also imparted to nanosponges (by adding magnetic particles 
into the reaction mixture). 
Mechanism of Drug Release
18 
The sponge particles have an open structure and the active is free to move in and out 
from the particles and into the vehicle until equilibrium is reached . In case of topical delivery, 
once the finished product is applied to the skin, the active that is already in the vehicle will be 
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absorbed into the skin, depleting the vehicle, which will become unsaturated, therefore 
disturbing the equilibrium. This will start a flow of the active from the sponge particle into the 
vehicle and from it to the skin until the vehicle is either dried or absorbed .Even after that the 
sponge particles retained on the surface of stratum corneum will continue to gradually release 
the active to the skin,  providing prolonged release overtime. 
 
Figure -5: drug release mechanism in Topical drug delivery. 
FACTORS AFFECTING DRUG RELEASE FROM NANOSPONGES
18
: 
 Physical and chemical properties of entrapped actives. 
 Physical properties of sponge system like pore diameter, pore volume, resiliency etc. 
 Properties of vehicle in which the sponges are finally dispersed. 
 Particle size, pore characteristics, composition can be considered as imperative 
parameters. 
 External triggers like temperature, pressure, and solubility of actives. 
Pressure: Pressure or rubbing can release active ingredient from Nanosponges onto 
skin. 
Temperature: Some entrapped actives can be too viscous at room temperature to flow 
spontaneously from sponges onto the skin but increased skin or environment can result 
in increased flow rate and ultimately drug release. 
Solubility: Sponges loaded with water soluble drug like antiperspirants and antiseptic 
release the ingredients in the presence of water. 
• ACTIVE 
INGREDIENTS 
Sponge 
• ACTIVE 
INGREDIENTS 
Vehicle 
• ACTIVE 
INGREDIENTS 
Skin 
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The nanosponges are encapsulate the drug molecule within its core. By the method of  
associating  with drugs, the nanoparticles can be classified into
74
: 
1. Encapsulating  nanoparticles:- These are represented by nanosponges and 
nanocapsules. Nanosponges such as alginate nanosponges, which are sponge 
like structure that carry the drug molecules. Nanocapsules such as 
poly(isobutyl-cyanoacrylate)  (IBCA) are also encapsulating  nanoparticles. 
They can entrap drug molecule in their aqueous core.  
2. Complexing nanoparticles:- These nanoparticle attract the molecule by 
electrostatic charges.  
3. Conjugating nanoparticles:- These nanoparticles links to drug through strong 
covalent bonds. 
 
 
PREPARATIONOFNANOSPONGES
21
. 
Nanosponges are prepared depending on type of delivery  system, polymers and 
nature of drug and solvents.  Various approaches used for formation of Nanosponges 
are: 
1.Polymerization: 
The polymerization process leads to the formation of a reservoir type of system,  which 
opens at the surface through pores. A solution of non-polar drug is made in the 
monomer, to which aqueous phase, usually  containing surfactant and dispersant to 
promote suspension is added. Polymerization  is effected, once suspension with the 
discrete droplets of the desired size is established; by activating the monomers either by 
catalysis or increased temperature. 
2.Quasi-emulsionsolventdiffusion 
The Nanosponges can also be prepared by quasi-emulsion solvent diffusion method 
using the different polymer amounts. To prepare the inner phase, EudragitRS100 was 
dissolved in suitable solvent. Then, drug can be added to solution and dissolved under 
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ultra sonication at 35°C.The inner phase was poured into the PVA solution in water 
(outerphase).  Following 60min of stirring, the mixture is filtered to separate then 
anosponges. The Nanosponges aredried in an air-heated oven at 40 ° C for 12hrs. 
3.Emulsion solvent diffusion method 
In  this method the two phases used are organic and aqueous. Aqueous phase consists  of 
polyvinyl  alcohol and organic phase include drug and polymer. After dissolving drug 
and polymer to suitable organic solvent, this phase is added slowly to the aqueous phase 
and stirred for two or more hours and then Nanosponges are collected by filtration, 
washed and then dried in  air at room temp or in vacuum oven at 40°C for 24hours. 
 
Polymers Used in Nanosponge Preparation: 
There are various polymers and crosslinkers are used in the preparation of nanosponges, 
listedinTable -1                                              Table -1 
Polymers Copolymers                 
Crosslinkers 
Hyper    cross    linked    
Polystyrenes, 
Poly(valerolactone Carbonyl   diimidazoles,   
Carboxylic   acid Cyclodextrines and   
Alkyloxycarbonyl Cyclodextrins, 
allylvalerolactone),Poly 
(valerolactone-
allylvalerolactone 
dianhydrides,                      
Diarylcarbonates, 
Dichloromethane, Diisocyanates, 
Diphenyl 
Methylβ-
Cyclodextrin,HydroxyPropyl 
β-Cyclodextrins, Ethyl  Cellulose. 
oxep nedione),Polyvinyl
alcohol. 
Carbonate,  Epichloridine,  
Gluteraldehyde, 
Pyromelliticanhydride,2,2-
bis(acrylamido) Acetic acid. 
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Some drugsformulated as nanosponges
18
are given in table -2. 
Table -2:Drugs used as Nanosponges. 
Drug Nanosponge 
vehicle 
Therapeutic indication 
Econazolenitrate EthylCellulose 
Polyvinylalcohol 
Antifungal 
Paclitaxel β-Cyclodextrin Cancer 
Tamoxifen β-Cyclodextrin BreastCancer 
Resveratrol β-Cyclodextrin Inflammation 
Cardiovascular diseases 
Dermatitis 
Gonorrhea 
Fever 
Hyperlipidemia 
Dexamethasone β-Cyclodextrin Braintumors 
Temozolam ide Poly 
(valerolactone- 
allylvalerolactone) Poly 
(valerolactone- 
allylvalerolactone- 
oxepanedione) 
Braintumors 
EVALUATIONOF NANOSPONGES 
1. Particle size determination
18
: 
  The particle  size can be determined by dynamic light scattering  using 90 plus 
particle sizer equipped with MAS OPTION particle  sizing software (Malvern zeta sizer).  From 
this the mean diameter and poly dispersity index can be determined. 
2. ZetaPotential
18 
 Zeta potential is a measure of surface charge. It can be measured by using additional 
electrode in the particle size equipment. 
3. LoadingEfficiency
18 
The loading efficiency of Nanosponges can be determined by the quantitative estimation 
of drug Loaded into Nanosponges by UV spectro photometer & HPLC methods. 
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4.  Microscopic study
18 
 Scanning electron microscopy (SEM) and Transmission electron microscopy (TEM) are 
used to study the microscopic character of nanosponge. Morphology of the Nanosponge is 
studied with SEM. 
5. CompatibilityStudies
18
 
 The compatibility study of drug with the adjuvants are determined by FTIR,TLC. 
Crystalline characteristics can be studied by powder X-ray diffraction (XRD) and Differential 
Scanning Calorimetry(DSC). 
6.Thin Layer Chromatography
18 
 In TLC, formation of the complex in nanosponge is determined by the Rf 
values. 
7.Solubility study
18 
 The Inclusion complexation are studied by  phase solubility method described 
by higuchi and Connors whichexamines the effect of a Nanosponge, on the solubility 
of drug. 
8.Single Crystal X-Ray Structure
18 
This method used to determine the detailed inclusion structure and mode of interaction. 
The interaction between the host and guest molecules can be identified and the precise 
geometrical relationship can be established. This information obtained during the analysis lead 
to know about the formation of inclusion complexes. 
9.Drug release study
18 
 Release study for the drug is done with dialysis membrane using Franz diffusion cell. 
10.Drug kinetic study
18 
 To investigate the mechanism of drug release from Nanosponge the release data  could 
be analysed using Zero order, 
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Firstorder, Higuchi, Peppas, Hixon-Crowell, Kopcha and Makoid-Banakar etc. models. 
The data can be analysed using graph pad prism software. 
11.Porosity
19 
 Porosity study is carried out to check the Nanochannels and nanocavities formed in 
Nanosponge. Porosity of Nanosponge is determined by Helium displacement method using 
Helium pynometer. 
12.Swelling and water uptake
19 
 For swellable polymers like polyamidoamine nanosponges, water uptake can be 
determined by soaking the prepared Nanosponges in aqueous solvent. Swelling and water up 
take can be calculated using equations. 
13.Resiliency(Viscoelasticproperties)
19 
 Resiliency of sponges can be modified to produce beadlets that is softer or firmer 
according to the needs of the final formulation. Increased crosslinking tends to slow down the 
rate of release. Hence resiliency of sponges will be studied and optimized as per the requirement 
by considering the releaseas a function of cross-linking with time.
 
ComparisonofSomeEffectiveVesicularSystems
19
. 
Liposome, niosome, ethosome, transferosome and nanosponge are colloidal drug delivery 
systems. They all are nanometric in size. Liposome, noisome and transferosomes have some 
stability problems which is discuss below in table but Nanosponge enhanced the stability of 
drug. 
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Table-3:Comparison of Nanosponge with Vesicular system.
 
Liposome Niosome Ethosome Transferosome Nanosponge 
Liposome consist of 
one or more 
concentric lipid 
bilayers, which  
enclose an internal 
aqueous volume. 
Niosomes are non- 
Ionic surfactant  
vesicles obtained             
on hydration of 
synthetic  nonionic 
surfactants, withor 
without 
incorporation      of 
cholesterol or other 
lipids. 
Ethosomes are lipid 
vesicles    containing 
phospholipids, 
alcohol(ethanol and 
isopropylalcohol)in 
relatively high 
concentration      and 
water. 
Transferosomes are 
vesicular        system 
consisting              of 
phosphatidyl choline 
and surfactants. 
Nanosponge are 
novel class of hyper- 
crosslinked polymer 
based colloidal 
structures consisting 
of solid 
nanoparticles with  
colloidal  sizes and            
nanosized cavities. 
The  composition of 
liposomes is 
phospholipids and 
cholesterol. 
They composed of 
non-ionic 
surfactants        and 
cholesterol. 
They composed 
mainly of 
phospholipids, high 
concentration of 
ethanol and water. 
They consists of 
phospholipids     and 
surfactants. 
They  composed  of 
polymers  and  cross 
linkers. 
Stability     
problems: 
due the formation of 
ice crystals in 
liposomes,             
the subsequent 
instability of  
bilayers  leads  to 
the leakage of 
entrapped material. 
The oxidation of 
cholesterol and 
phospholipids also 
leads to the 
formulation 
instability. 
Stability  problems: 
fusion, aggregation, 
sedimentation and 
leakage on storage. 
The Hydrolysis of 
encapsulated drug. 
Ethosomes            
has initiated a new 
area in vesicular 
research for 
transdermal        
drug delivery which 
can provide   better   
skin permeation           
and stability than 
liposomes. 
Application of 
ethosomes provides 
the  advantages  
such as improved 
entrapment and 
physical stability. 
Stability       
problem: 
chemically unstable 
because of their 
predisposition         
to oxidative 
degradation. 
Nanosponge          
are chemically and 
physically stable. 
They    increase    the 
stability and 
bioavailability, 
modify  drug  release 
and reduce side- 
effects. 
 
APPLICATIONS OF NANOSPONGE: 
 Topical delivery19: 
             Local anesthetics, antifungal and antibiotics are among the category of the drugs that 
can be easily formulated as topical Nanosponges. A wide variety of substances can be 
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Incorporated into a formulated product such as gel, lotion, cream, ointment, liquid, or powder. 
 Enhanced Solublity19 
The Nanosponge system has pores, that increase the rate of solubilisation of poorly 
soluble drug  by entrapping such drugs in pores. Due to nanosize surface area significantly 
increased and increase rate of solubilisation. 
 Nanosponge as chemical sensor19: 
 Nanosponges which are the type of “ metaloxides ”act as a chemical sensors which is 
used in highly sensitive detection of hydrogen using Nanosponge titania. Nanosponge structure 
initially have no point of contact so there is less hinderance to electron transport and it results in 
higher 3D interconnect Nanosponges titania which is sensitive to H2 gas. 
 Used as Taste masking agent.40 
 Chemotherapy19 
 The tiny sponges are filled with drug and expose a targeting Peptide that bind to 
radiation induced cell surface receptor on tumor. When the sponge encounter tumor cell they 
stick to surface and triggered to release cargo. One of the important drug formulated as 
Nanosponge is paclitaxel, the active ingredient in the anti-cancer therapy Taxol. 
 
 
                    Figure-6: Nanosponge particle attaching to human breast cancer cells
16 
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 In anti viral therapy17: 
Nanosponges can be useful in the ocular, nasal and pulmonary administration routes. The 
selective delivery of antiviral drugs or small interfering RNA (siRNA)  to the nasal epithelia 
and lungs can be accomplished by nanocarriers in order to target viruses that infect the RTI such 
as respiratory sinctial virus, influenza virus and rhinovirus. They can be used for Human 
Immunodeficiency Virus (HIV), HepatitisB Virus (HBV) and Herpes Simplex Virus 
(HSV).Drugs used are zidovudine, saquinavir, interferon-α, acyclovir, nelfinavir etc. 
 In protein drug delivery17 
Bovine serum albumin(BSA)  protein  is unstable in solution form so stored  in  lyophilized 
form. Swellable cyclodextrin based poly(amidoamino)Nanosponge enhanced the stability of 
proteins like BSA. Nanosponges have also been used for enzyme immobilization, protein 
encapsulation, and subsequent controlled delivery and stabilization. 
 In oxygen delivery system19,54 
Cyclodextrin Nanosponges  have  also  been  developed  as oxygen delivery system. 
 Nanosponge has the ability to store and to release oxygen slowly overtime. Oxygen-
filled nanosponges  could supply oxygen to the hypoxic tissues which are present in various 
diseases. 
Characterized by using a, ß and ϒ  cyclodextrins and this are suspended in water and get 
saturated with water. A silicone form of membrane can also be used for oxygen permeation with 
the help of nanosponge/ hydrogel system. They can also applied it to hypoxic tissues caused in 
various type of diseases. 
 
            Toxin absorbing Nanosponges used to  absorb Toxin of staphylococcus aureus which 
produce resistance to Methicillin
37
. 
 More effectiveness than direct injection:56 
Recent research suggests that nanosponge could be up to five times more effective at 
reducing tumor growth than direct injection. The drug delivery system is likened to be filling 
virus-sized sponges with an anti-cancer drug, attaching chemical linkers that bond to a receptor 
on the surface of tumor cells, then injecting the sponges into the body. When the sponges come 
into contact with a tumor cell, they either attach to the surface or are sucked into the cell, where 
they off-load their deadly contents in a predictable and controlled manner. 
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 Novel flame retardants containing cyclodextrin nanosponges and phosphorus compounds 
to enhance EVA combustion properties
69
 
  A novel flame retardant in tumescent system, aimed to improve the fire stability of ethylene 
vinyl acetate copolymer (EVA), has been prepared by melt blending of the copolymer and a 
complex of cyclodextrin nanosponge-phosphorus compounds. As compared to traditional 
systems, this complex which is stable in processing conditions, has the advantage that 
nanosponges act as both carbon sources and foam forming agents while the phosphorus 
compounds are able to directly generate phosphoric acid in situ. In this context, cyclodextrin 
nanosponges undergo dehydration in presence of the acid source, generating water vapour and 
char, and thus protecting the copolymer against combustion.  
 OtherApplications 
       Biomedical Application, 
        Analytical Application, 
        For Hydrogen storage, 
        In Agriculture, 
        In Floriculture, 
        In Food Industry, 
        For water Purification, 
        For Oil Cleaning, 
        As Novel flame Retardants, 
        Against pore forming Toxins and superbug infections, and 
        Micro patterning of Mammalian cell. 
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1. Dr Prathima srinivas et al 31 formulated and Evaluated Voriconazole Nanosponges for 
Oral and topical Delivery as Tablets and Gel. Voriconazole Nanosponges were prepared 
by Emulsion Solvent Evaporation Technique with three different Polymers. Final 
formulations and Nanosponges were evaluated for Drug content, Entrapment efficiency, 
Physical parameters, FTIR Study, In-vitro and in-vivo study, and Anti microbial activity. 
From the above evaluation they concluded that the three polymers used were efficient 
carriers for Voriconazole Nanosponge showing Diffusion controlled release. 
2. Raja CH. NV. et al 36 fabricated and Evaluated Ciprofloxacin loaded Nanosponges for 
sustained release. Five batches of Nanosponges using different proportion of Ethyl 
cellulose were prepared by solvent evaporation method. The Nanosponges were 
evaluated for Characterization by Scanning electron microscopy, Solubility study, In-
vitro dissolution study, and Drug entrapment efficiency. Thereby they concluded that the 
Final batch (F5) is considered as a best entrapped and has a greater percentage drug 
release.  
3.  Gautam Seema et al 33 developed and evaluated curcumin loaded Nanosponges for 
colon drug delivery. Six batches of Nanosponges were prepared and zeta potential, Drug 
content, Drug entrapment efficiency, Surface characteristic by SEM, Particle size, FTIR, 
DSC, Stability studies, In-vitro drug release, and Kinetic models of dissolution profiles 
were evaluated. Thereby they concluded that curcumin and Eudragit L -100 1:3.5 (F4 
batch) has found to be the optimum formulation, that has a significant improvement of 
curcumin performance from Nanosponges compared to pure curcumin and other 
formulation. 
4. P.Suresh Kumar et al 37 formulated and evaluated Miconazole nitrate Loaded 
Nanosponges for vaginal drug delivery. Nanosponges were prepared using different 
ratios of beta cyclodextrin and Di phenyl carbonate. The Miconazole nitrate was loaded 
into the beta cyclodextrin Nanosponges by solvent evaporation technique using various 
solvents. Nanosuspension was prepared with the Miconazole Nanosponge. That 
nanosuspension is used for the preparation of Gel using Carbopol 934 as gelling agent. 
Both the Nanosponge and Gel were evaluated. Thereby they concluded that the   
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optimized formulation has good spreadability, extrudability, mucoadhesive nature and 
has sustained release. 
 
5. Renuka Sharma et al 34 fabricated and Evaluated Econazole nitrate Nanosponges as 
topical hydrogel. Econazole Nanosponge were prepared by using various concentration 
of ethyl cellulose and evaluated for entrapment efficiency, in -vitro drug release size 
measurement, Rheological properties. For hydrogel the Equilibrium swelling study, 
viscosity analysis, texture analysis, in-vitro permeation study has evaluated. 
 
6. Fei Wang, et al38 formulated Hydrogel Retaining Toxin – Absorbing Nanosponges for 
Local Treatment of Methicillin Resistant Staphlococcus aureus infection. The 
Staphlococcus aureus which are resistant to the methicillin due to their toxin activity 
towards the drug. These type of toxins which were forming pore and constitute  important 
bacterial virulence factors. These toxins disrupt cells  by forming pores on cellular 
membranes and altering their permeability for bioactivity. Hybrid nanostructures like 
Nanosponges may has ability to absorb toxins and by reducing their effect. That can be 
proved by in-vitro  -toxin Neutralization study, Live whole body imaging of mice to 
study Nanosponge retention, in-vivo  -toxin Neutralization study and in- vivo 
Detoxification efficacy against localized MRSA infection. 
 
7. Gouri Shankar and Y.K. Agarwal40 formulated and Evaluated  -cyclodextrin 
Nanosponges of a poorly water soluble drug.  -cyclodextrin Nanosponge  were prepared 
and Simavastatin was added to it. The Simvastatin Nanosponges are evaluated for the 
Particle size. Polydispersity, Zeta potential, Entrapment efficiency, FT-IR, DSC,XRD, 
Mucoadhesive strength ,in-vitro release study, Kinetics study, and Stability study.  
Higher Solubilization and prolonged release of Simvastatin Nanosponges served the 
purpose of synthesizing Nanosponges. Thereby they concluded that the  -cyclodextrin  
based  Nanosponge was an effective nanocarrier for the delivery of simvastatin. 
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8. Monica R. P. Rao et al41 developed and Evaluated the Nanosponge- based Pediatric-
controlled release dry suspension of Gabapentin for reconstitution. Nanosponge of 
Gabapentin were formulated using  -cyclodextrin by melt method. The Nanosponge drug 
complex were characterized by FT-IR, DSC and PXRD as well as evaluated for taste and 
saturated solubility. Then it was coated with Ethyl cellulose and Eudragit RS 100. It 
shows the release of  drug from Nanosponge was in controlled manner, as well as the 
taste of Gabapentin was masked. Leaching of drug is insignificant shows the stability of 
Nanosponge. Thereby they conclude that the Nanosponge prepared with  -cyclodextrin 
was an ideal nanocarrier for controlled release. 
 
9. Kurhe, et al42describes Scaffold based drug delivery system :A Special emphasis on 
Nanosponge. Nanosponges were prepared to have ability to encapsulate either 
hydrophilic or lipophilic drug and release the drug in a controlled and predictable fashion 
at the target site. Thereby they concluded Nanosponges increases the drug solubility 
ofpoorly water soluble drugs and protects the drug from physiochemical degradations. It 
can be developed asdifferent dosage forms like Paretrals,aerosol, topical, tablet and 
capsule. Thus, Nanosponges are a Boon for targeted and site specific drug delivery 
system. 
 
10. Shastrulagari Shivani et al43 reviewed Nanosponge – novel emerging drug delivery 
system. Types of Nanosponge, advantages, Polymers and cross linker used are reviewed. 
Method of preparation of Nanosponge, Factors influencing  Nanosponge, characterization 
and applications.  
 
11. P.Suresh Kumar. et al 44 prepared and Evaluated Clotrimazole loaded Nanosponges 
containing vaginal Gels. Vaginal gel were formulated and the various evaluation are 
carried out for Nanosponge and for the Gel. Thereby they concluded that the Nanosponge 
gel prepared with HPMC showed good extrudability, homogeneity, spreadability and 
required diffusion rate in comparison with other formulations and selected as suitable 
carrier to be delivered through vaginal route at controlled rate. 
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12. Satyen J. torne, et al 45 prepared and Evaluated for Enhance oral paclitaxel 
bioavailability after administration of paclitaxel loaded Nanosponge. The prepared 
Nanosponge is evaluated for general test for Nanosponge and the pharmacokinetics of 
Paclitaxel through Nanosponge.The plasma concentration of paclitaxel after the oral 
administration were significantly higher than the Taxol at the same dose shows the 
increased effect than conventional dose/ 
 
13. Marzouk M.A., et al 46prepared and Evaluated the Nystatin Topical formulations with 
various Penetration enhancers. All the general parameters are evaluated for the gel and 
compared with the plain gel and concluded that the penetration enhancer used Propylene 
glycol showed the highest effect in the amount drug permeated followed by 
dimethylformamide. The antifungal activity of all Nystatin gels was found  to be greater 
than that of commercial nystatin cream. 
 
14. Bazigha k. Abdul Rasool, et al47 in-vitro release study of  Nystatin from chitosan buccal 
gel. Bioadhesive Nystatin gel with chitosan as gelling agent and various enhancers. All 
the general tests for gel were evaluated and then the Antifungal effect of Nystatin was 
carried out. From the above study thy concluded that the 5% Chitosan with10% w/w of 
PG as solubilizing agent has best activity and in-vitro release shows the enhancement of 
solubility  over commercial product. 
15. Reeta T.Metha, et al48 formulated the Liposome encapsulaed Nystatin for systemic 
Candidiasis. Liposomes are formulated using various lipids and reagents. That liposomes 
are subjected for all the tests and concluded that the formation of liposomes reduces the 
toxicity and improve the release. 
16. Rodino S, et al49 Nystatin Determined quantitatively by spectrometric method. The 
average Nystatin content resulting from the five determination differs from the expected 
value not more than 3.15% of the average.  Thereby they concluded that the analytical 
method based on exploiting photosensitivity and selective photo transformation of the 
active substance proved to be reliable for analytical control. 
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17. Gabriela Badea, et al50 formulated Nystatin loaded nanostructured carriers for the 
influence of basil oil extract on the antioxidant and antifungal activity. Lipid 
nanoparticles were prepared with basil oil and evaluated for the anti oxidant activity and 
anti microbial activity. Charcterization of size , uniformity, and stability of the 
nanoparticle is measured. The antioxidant activity was maintained in the area of a high 
ability scavenge free radicals. Thereby they concluded that the NLC based on 2% basil 
oil and loaded with 1%nystatin was found to be the most active against Candida albicans. 
 
18. Sachin S. Salunkhe ,et al51 investigated Nystatin loaded Liposomal gel for topical 
application  by factorial design. Nystatin liposomes were prepared by ethanol injection 
method and the effect of variables , size distribution , zeta potential, entrapment 
efficiency, and Skin permeation and drug deposition study were done. For the liposomal 
gel, the rheological study, drug content, content uniformity and stability studies were 
performed. The results were obtained by factorial design and concluded that the 
liposomal gel were found to be significantly increase the skin permeation and deposition 
in comparison to standard reference product, and has potential application in topical 
delivery. 
 
19. Ruba Kello,52 prepared Polyethylene Glycol Novel based Nystatin and Triamcinolone 
acetonide ointment. Prepared ointment is  subjected to Stability studies, and they 
concluded that it polyethylene glycol 1500 and polyethylene glycol 400 can be used as an 
alternative ointment base for Nystatin and Triamcinolone acetonide. 
 
20. Tahseen h. Nasti, et al77 prepared and evaluated the pH-sensitive Nystatin liposomes 
against Crytococcus neoformans in murine model. The pH sensitive Nystatin  liposomes 
were prepared by Egg Phosphatidylcholine, cholesterol and mixing the DOPE and 
CHEMS in the ratio of 2:3.all the ingredients were mixed in a round bottomed flask and 
minimum quantity of chloroform or methanol (1:1) . Solvents were carefully evaporated 
to for liposomes. Antifungal susceptibility test were carried out in mice.Results were 
compared with Nystatin. As they concluded that the infection was subsided owing to the 
use of pHsensitive Nystatin liposomes that release substantial drug at the pH favorable 
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for Cryptococcus neoformans. Nystatin , toxic in free form, can be made more effective 
and safe entrapping it within pHsensitive  liposomes for treatment of fungal disease. 
 
21. Mohammad Barzegar-Jalali,et al53formulated and evaluated Nystatin suspensions to 
determine Effect of different buffered and unbuffered dispersion medium on the physical 
and chemical stability. The Prepared nystatin suspensions were evaluated for the 
Sedimantation volume, resuspendability, Freeze-thaw cycling test, chemical testing like 
Arrhenius accelerated stability test and shelf life. Thereby they concluded that the 
buffered cellulosic suspending agent containing  nystatin suspension gave stable 
suspension when compared to unbuffered vehicle. 
 
22. Kunikazu Mobibe, et al54 formulated and evaluated the Nystatin liposomes  for the 
Encapsulation characteristics by effects of cholesterol and polyethylene glycol 
derivatives. The prepared liposomes are evaluated for the Fluoresence measurement of 
nystatin binding. They concluded that the encapsulation of liposomes in relation to the 
incorporation of cholesterol and DSPG-PEG, High encapsulation efficiency was obtained  
in CH-free PEG-liposomes. Molecular interaction between nystatin and DSPE-PEG 
appears to invovlve in the interaction of amino group of nystatin with the phosphate 
group of nystatin in the liposomal membrane. These results may help in the development 
of effective pharmaceutical formulations for injectable hydrophobic drugs with reduced 
side effects. 
 
23. Akhani Jolly R*, et al59 formulated  developed and evaluated the in situ gel for vaginal 
drug delivery of anti fungal drug. When poloxamers PF 127 and PF 68) were used in 
combination for developing thermosensitive and mucoadhesive in situ gel, low to 
moderate amounts of HPMC K4M and PF68 were to be used to achieve the desired 
gelation temperature, gel strength, mucoadhesion, drug release profile and viscosity 
required for a sustained vaginal drug delivery system of nystatin. It was concluded that 
the amounts of  HPMC K4M had a significant effect on bioadhesion force and gel 
strength of the formulated thermosensitive and mucoadhesive in situ gel. The quadratic 
mathematical model developed is applicable to predicting  in situ gel vaginal 
formulations with desired characteristics. 
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24. Rawia  M.  Khalil* et al66 formulated and characterized the nystatin-loaded 
nanostructured lipid carriers for topical delivery against cutaneous candidiasis . 
Nys NLC is prepared with various surfactants,  and Lipids. The prepared NLC 
were evaluated for Particle size, Entrapment, TEM, DSC, Stability and Release , 
antimicrobial activity. Thereby they conclude that the prepared Nys NLC is 
better than the commercial products. 
 
25. Kunikazu Moribe, et al67 investigated the molecular state of Nystatin 
encapsulated in liposomes by spectrometrically. Liposomes with DPPC, 
DPPC/CH, DPPC/DSPE-PEG, DPPC/CH/DSPE-PEG, DPPC/CH/DSPE-PEG. 
The molecular state of Nystatin in liposomes are subjected to spectrometically, 
thereby they concluded that compared with AmB, Nystatin does not readily form 
a complex with DSPE-PEG and the enhanced encapsulation of Nystatin would be 
attributed to the CH-free liposomes. DPPC liposomes shows the least stability in 
these composition. 
 
26. A. Hassan, et al68 confirmed Candida albicans endogenous fungal 
endophthalmitis in a patient with chronic Candidiasis.  They concluded that 
confirmed C. albicans endophthalmitis in a patient with chronic vaginal 
Candidiasis, and need a particular importance in patients with additional 
immunosuppressive risk factors. So need to carefully monitor patient’s eyes or 
administer antifungal prophylaxis in patients with active genital Candidiasis 
undergoing procedures. In this case conventional microbiological  laboratory 
diagnostics were negative and EFE was only confirmed with molecular 
techniques. This highlights the need to utilize DNA diagnostics in the early 
identifications of at risk patients. 
 
27. Journal of Antimicrobial Chemotherapy69 studied the use of fluconazole and 
itraconazole in the treatment of Candida albicans. In this article they concluded 
that fluconazole  remains a first-line antifungal agent of choice for the treatment 
of C. albicans infections, because of its well-known efficacy and safety profile; 
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its suitability for use in children, the elderly and patients with impaired immunity; its 
range of formulations; and its cost. 
 
28. Mary K. Truhlar,et al 69 quantified the antifungal activity of Nystatin 
incorporated in denture liners by new assay technique. Preparation incorporating 
higher concentrations of nystatin were more potent inhibitor of Candida albicans 
growth, and loss of antifungal activity for all concentrationswas the greatest 
from day 0 to 2.Incorporating  a single doseof an antimycotic agents into the 
reline material of the denturethat allows release of the agent over 2 week period 
is a treatment modality that offers considreable promise for the management of 
oral candidiasis. 
 
29. B.Indira, et al72 reviewed Nanosponges, a New Era in Drug Delivery. They 
Reviewed on the Nanosponge about the Advantages, Disadvantages, Method of 
Preparation,  Polymers and crosslinkers Used, Factors infiuencing Nanosponge, 
Characterization of Nanosponges, and their applications. They concluded that 
this new invention, nanosponges will pave a way in overcoming the challenges in 
designing of targeted drug delivery systems because of their ability to 
accommodate either hydrophilic or lipophilic drugs and release them in  a 
controlled and predictable manner at specific site in the body. The release rate 
can be modulated by controlling the polymer and cross linker ratio. The 
nanosponges have been found to possess a profound ability to protect essential 
biomarkers in diseases (cancer for example) and biocatalysts from 
physicochemical degradation. In near future they stand as milestones in drug 
delivery. 
 
30. E. K.Patel et al73 reviewed Nanosponge and micro sponges  a Novel drug 
delivery system. They reviewed about all the aspect of Nanosponge and 
elaborated about the uses of prepared Nanosponges.  Camptothecin (CAM), a 
plant alkaloid and potent antitumor agent, has a limited therapeutic utility 
because of its poor aqueous solubility, lactone ring instability and serious side 
effects. Cyclodextrin based nanosponges(NS) are a novel class of cross-linked 
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derivatives of cyclodextrins. They have been used to increase the solubility of 
poorly soluble actives, to protect the labile groups and control the release. This 
study aimed at formulating complexes of Camptothecin with ßcyclodextrin based 
nanosponge. They concluded that the Nanosponges are a Nanosized particle 
entrap wide variety of products, enhance solubility,  provide prolonged use and 
provide patient compliance with the formulation. 
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AIM OF WORK 
The aim of the present study is  
 To formulate Nystatin loaded Nanosponge using various polymers.  
 To provide an efficient dosage form.  
PLAN OF WORK 
    The present work is designed and planned as follows: 
 Drug-polymer compatibility studies by FT-IR. 
 Determination of  λ max of Nystatin.  
 Preparation of Calibration  curve of Nystatin.  
 Formulation of Nystatin loaded Nanosponge 
 Formulation of Nystatin Nanosponge using different polymers (Ethyl cellulose and 
Polymethyl methacrylate) at different ratios (Drug:Polymer-1:1,1:2,1:3,1:4and 1:5) 
using Solvent Emulsion evaporation Method. 
 Characterization of Nystatin loaded Nanosponges 
 
      Determination of physical properties. 
 
      Determination of drug content. 
 
      Determination entrapment efficiency. 
 
      Determination of particle size distribution. 
 
      in-vitro release studies of Nystatin loaded Nanosponge.  
      Kinetics of drug release. 
      Morphology of Nanosponge by Scanning electron microscopy(SEM) technique. 
      Stability studies.    
  Formulation of Nystatin loaded Nanosponge Gel for optimized product: 
  Evaluation of Nystatin loaded Nanosponge Gel. 
        Determination of physical properties.  
      Determination of drug content. 
        In-vitro release studies of Nystatin loaded Nanosponge Gel.  
       Antifungal activity of the Nystatin loaded Nanosponge Gel.                                       
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RATIONALE OF THE STUDY
 
Fungal Infections have been increasing in incidence in the human population over the 
last 15 years or so, largely as a consequence of increased numbers of cancer and immune 
compromised patients, who are at risk owing to weakened immune systems and chronic nature of 
the disease.  
Systemic fungal infections are more serious as they are usually more difficult to 
diagnose, are chronic in nature, and in some cases, can become life-threatening. They occur more 
frequently in individuals with compromised immune systems (AIDS patients; transplant patients; 
cancer patients). Prophylactic treatment is sometimes indicated in AIDS patients and bone 
marrow transplant patients, but risk of developing resistance is high. Life-threatening infections 
require the use of more potent but much more toxic antifungal. 
 Superficial fungal infections are almost always caused by dermatophytes or yeasts. In 
some instances, they can be rather tenacious, requiring very long treatments, sometimes with 
both oral and topical drugs. 
RATIONALE OF SELECTION OF DRUG
61 
  Nystatin (Nys) is a polyene antifungal antibiotic, one of the oldest antifungal drug, 
produced by Streptomyces noursei strains  Nys monomers selectively interact with ergosterol 
causing membrane disruption and eventual cell death. Nys possesses a broad spectrum with both 
antifungal and fungistatic activity,  being effective against azole-resistant strains of Candida and 
amphotericin B resistant strains of Candida albicans. Nys is indicated for treatment of Cutaneous 
and mucocutaneous fungal infections caused by Candida species, the main yeast capable of 
infecting the oral mucosa, C. albicans being the most common species isolated . Oral Candidiasis is 
not a lethal disease in healthy patients. It is mainly caused by antibiotic or corticosteroid treatment 
and dental prosthesis. However, it must be treated to avoid chronic and systemic invasions of other 
tissues, especially among patients with diabetes mellitus, immune compromised or under aggressive 
treatments (e.g. chemotherapy) to prevent opportunistic invasive fungal infections. 
 The presence of a large lactone ring with several double bonds renders it an 
amphiphilic and amphoteric molecule with poor solubility in aqueous media (360 mg/L at 
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˚ 
C), which reveals great
 
formulation
 
challenges. This fact support
 
that
 
an increasingly 
important area of pharmaceutical research is
 
focused
 on ﬁnding safe and effective methods of 
solubilizing poorly
 
soluble
 
drugs. 
 Adverse effect of Nys is very rare. From Neonates to Elderly can use Nys, even Pregnant 
women can use it safely.
62
 Cost of Nystatin  cream when compared to other antifungals is low. 
 
RATIONALE FOR THE SELECTION OF DOSAGE FORM.
20,65 
  Nanosponge are mainly for Topical drug delivery.  It is very much suitable for 
antifungal agents. Nanosponge is a nano sized particle, has larger surface area, thereby the 
penetration is high when compared to other conventional products. Low solubility drugs  
formulated as Nanosponge may increase the solubility thereby increase the release and activity. 
Stability of Nanosponge is higher than most of the novel formulation. 
 Nystatin has only topical action, there is no systemic effect, and it is slightly soluble in 
water, hence preparations as Nanosponge increases its effect by increasing solubility. 
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CANDIDA SPECIES 
 Candida species is the most common cause of opportunistic fungal infection worldwide. 
Candida is the major fungal pathogen of humans, causing diseases ranging from superficial 
mucosal infections to disseminated, systemic infections that are often life threatening. A striking 
feature of its pathogenicity is ability to grow in yeast, pseudohyphal and hyphal forms. The 
hyphal form has an important role in causing disease by invading epithelial cells and causing 
tissue damage. Among Candida spp., Candida albicans is the most common infectious agent. 
This dimorphic yeast is a commensal that colonizes skin,  the gastrointestinal  and  the  
reproductive  tracts.  Non-C.  albicans  species  are  also  emerging pathogens and can also 
colonize human mucocutaneous surfaces. The pathogenesis and prognosis of candidial infections 
are affected by the host immune status and also differ greatly according to disease presentations. 
Candidiasis is also technically known as candidosis, moniliasis   and   oidiomycosis
22 
. 
Table-4 : Candida species implicated in human infections. 
Common species Less common species Rare species 
Candida albicans 
Candida glabrata 
Candida dubliniensis 
Candida famata 
Candida blankii 
Candida bracarensis 
Candida tropicalis Candida 
parapsilosis Candida krusei 
Candida inconspicua 
Candida lipolytica 
Candida metapsilosis 
Candida catenulate Candida 
chiropterorum Candida ciferri 
Candida guilliermondii 
Candida lusitaniae 
Candida norvegensis 
Candida orthopsilosis 
Candida eremophila 
Candida fabianii 
Candida kefyr Candida pelliculosa 
Candida rugosa 
Candida fermentati 
Candida freyschussii 
 Candida zeylanoides Candida haemulonii 
Candida intermedia 
 Candida lambica 
Candida magnolia 
Candida membranae faciens 
Candida nivariensis 
Candida palmioleophila 
Candida pararugosa 
Candida pseudohaemulonii 
Candida pseudorugosa 
Candida pintolopesii 
     Candida utilis 
Candida valida 
Candida viswanathii 
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Candida albicans 
 It is a diploid yeast with two pairs of 8 chromosomes. Its genome size is about 16 Mb. It 
possesses 6,159 coding genes. It is the predominant cause of invasive fungal infections. People 
at risk include those suffereing from HIV, cancer and intensive care unit patients for example 
those undergoing major surgery and organ transplants. 
Candida glabrata (Torulopsis glabrata) 
 It is a small, haploid, monomorphic yeast with 13 chromosomes  and  a  genome   size  
of   12.3  Mb.   It possesses 5283 coding genes. It has become important because of its 
increasing incidence worldwide and decreased susceptibility to antifungals. Its emergence is 
largely due to an increased immunocompromised patient population and widespread use of  
antifungal drugs.  In many hospitals, C. glabrata is the second most common cause of 
candidemia. 
Candida tropicalis 
 It is a diploid, with 10 to 12 chromosomes and a haploid genome size of  15 Mb.  It  
possesses  6258  genes.  C. tropicalis is the third or fourth most commonly recovered Candida 
species from  blood cultures. C. tropicalis has progressively been observed to be the 
commonest cause of invasive candidiasis in neutropenic patients such as those with acute 
leukaemia or those who have under- gone  bone  marrow  transplantation. 
Candida parapsilosis 
It is a diploid or aneuploid with 14 chromosomes and a genome size of 16 Mb. It 
possesses 5733 genes. It is one of the principal causes of invasive Candidiasis. In most parts of 
the world, it is the third most common cause of candidemia especially in patients with 
intravenous cathe- ters, prosthetic devices, and intravenous drug use. It is one  of  the  most  
common  causes  of  candidemia  in neonatal intensive care units. 
Candida krusei 
It is a diploid, with 3-5 chromosomes and genome size of 11 Mb. It is the fifth most 
common bloodstream isolate, although, less common (1 to 2%), C. krusei is of clinical 
significance because of its intrinsic resistance to fluconazole and reduced susceptibility to most 
other antifungal drugs. It is frequently recovered from patients with hematological malignancies 
complicated by neutropenia tends to be associated with higher mortality rates (49 vs 28% with C. 
albicans), and lower response rates (51 vs 69% with C. albicans.. 
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Candida guilliermondii (teleomorph-Pichia guilliermondii) 
It is a haploid. It is reported to have genome size of 12 Mb and possess coding genes 
5920. It has been isolated from environmental surfaces and from the skin and nails of 
healthcare workers. It has been shown to cause hematogenously disseminated Candidiasis. 
Candida   lusitaniae   (teleomorph-Clavispora lusitaniae) 
It is a haploid. It has genome size of 16 Mb. Among, the rare  non-albicans  Candida  
species,  it  has  emerged during the last 20 years as an important nosocomial pathogen 
throughout the globe. 
Candida kefyr 
 
It consists of 18 chromosomes. Candida kefyr was only isolated from urine cultures 
(Weichert et al., 2012). It has been reported to cause systemic Candida infection in patients 
with neutropenic leukemia and in a woman with underlying heart disease. Very recently, it has 
been described as a pathogen causing invasive fungal enteritis in a patient with underlying 
haematological disease following  bone  marrow  transplantation.  
 
Major types of Candidiasis 
  Candidasis is an acute or chronic infection produced by Candida, generally limited to the 
skin and mucous membranes, but it could produce a serious systemic disease. 
Mucosal candidiasis 
 
Candidal infections are restricted to non-sterile mucosal surface for example 
oropharyngeal and vulvuvaginal Candidiasis. 
 Oropharyngeal candidiasis (OPC) 
 
Oral  candidiasis  is  one  of  the  most  common,  oral mucosal infections seen in persons 
with HIV.   Candida  is  commensal  organism  and  part  of normal oral flora in about 30 to 
50% of the population. There are three general factors that may lead to clinically evident oral 
candidiasis : immune status of  host, oral mucosal environment and particular  strain of  C.  
albicans  (hyphal form is usually associated with pathogenic infection). 
The ability of the yeasts to overcome host clearance mechanisms and to colonize surfaces 
can be considered as a risk factor for oral infection. The balance between Candida   colonization   
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and   candidiasis  relies  on   the balance  between  pathogen  characteristics  (e.g. production  of  
adhesins,  secreted  aspartylproteinases) and host factors. 
 
 
 
                                        
                                                                   
      Figure-7 : Oral Candidiasis22.                                           Figure-8  : Cutaneous Candidiasis27 
 
 
  
Figure-9 :Vulvovaginal  candidiasis
22
                        Figure-10   : Congenital Cutaneous candidiasis
27
. 
 
 
 
Vulvovaginal candidiasis (VVC) 
 
Vaginal candidiasis is the most frequent reason for gynecology consultation in 
primary health care services. Disease is usually associated with considerable morbidity, 
healthcare cost, discomfort, pain and sexual functioning; however, it is seldom life 
threatening. The symptoms associated with VVC are eczematoid dermatitis lesions that 
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sometimes show vesicular   and   grey-white   psuedomembrane,   vulval pruritis, burning, 
erythema and curd like discharge. 
 
 
Cutaneous candidiasis 
 
Cutaneous candidiasis is usually secondary infection of skin  and  nail  (body  folds)  in  
predisposed  patients.  It occurs as a sub-acute or chronic infection. Disease involvement may be 
localised or generalised to the skin or nails. The spectrum of cutaneous candidiasis includes 
diaper rash, intertrigo candidiasis, Candida folliculitis, Otomycosis, Onychia and Paronychia. It 
usually occurs in warm, moist and creased area, such as axillary folds, inguinal or intergluteal   
areas.   It   is  fairly  common   opportunistic disease and usually lead to maceration and 
trauma in skin. It is commonly found in diabetics and obese people. Other predisposing factors 
are antibiotic and oral contraceptives  become  macerated. 
 
Invasive candidiasis 
 
Invasive  infections can  involve virtually  any  organ.  C. albicans continue to account 
for the majority of invasive fungal infections,  there has been a recent increase in disease due 
to non-albicans Candida species (and antifungal-resistant Candida isolates). 
 
Systemic or disseminated candidiasis 
Severe organ invasive or systemic hematogenously disseminated candidiasis is 
characterized by spreading of the Candida cells into almost the entire body with a tendency to 
create abscesses in vitally important organs, inducing their failure which leads to mortality in 
~50%  of  all  cases,  irrespective  of  administration  of intensive antifungal therapy. 
Risk   factors   for  mucocutaneous  candidiasis may  include
24
: 
I. Cutaneous candidiasis  
    a.  Diabetes  mellitus 
b. Tropical  environment 
 c.  Obesity 
d.  Use of systemic  corticosteroids or anti- biotic  therapy 
e.  Neutropenia 
f.  HIV  infection 
g.  Other  immunocompromised  states 
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h.  Occlusion  (e.g.,  diapers,  casts.  Dressings) 
i.  Diseases  which  disturb the integument(e.g.,  psoriasis.  contact  dermatitis) 
j. Other 
2. Oral  candidiasis 
a.   Use of broad-spectrum antibiotics systemic, topical, and inhalational cortico 
steroids;  and cytotoxic  drugs 
b.  Radiation  therapy 
c. HIV Infection 
           d.  Other  immunocompromised  states  
e.  Age  (i.e ,  infants  and elderly) 
f. Occlusion  (e.g.,  dentures) 
g.  Other 
 
Diagnosis
23 
A.  Clinical 
I. History  may  include 
a.  General  medical  history,  especially  but not limited  to: 
1. History   of weight  loss   or  weight gain 
2. Endocrine diabetes  mellitus 
                 3.  Risk  factors  for HIV  disease 
4. Presence  of other  risk factors. 
         5. Use of systemic  medications 
        6. Other 
b.  Sexual  practices 
c.  Recurrent infections 
d.  Duration  of condition 
e.  Current   treatment(s)   topical   and  systemic  of 
1.  Mucocutaneous candidiasis 
2. Other  disease 
f.  Past  treatment(s) topical  and  systemic of 
1.  Mucocutaneous candidiasis 
2 Other  disease 
g.  Family   history   of  diabetes   mellitus and/or  mucocutaneous candidiasis 
h.  Occupation 
i.  Dermatophytic   infection,   particularly tinea  pedis,  tinea cruris 
j.  Drug  allergies 
k.  Other 
II. Physical  examination may  include 
a.  General  physical  examination as  indicated 
b.  Examination  of the  involved  area,  but special  attention  may  be directed  to 
1)  Skin  folds 
2) Diaper area 
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3) Comers of mouth and mucous membranes  (e.g.,  perleche) 
4) lnterdigital  spaces 
5) Scrotum,  glans  penis  and foreskin, crural  folds,  gluteal  area 
6) Perianal  area 
7) Vagina,  vulva 
8)  Axillae 
9) Nail unit 
10) Other 
c.  Extent  of involvement 
d.  Clinical  appearance  
e.  Associated  findings 
1)  Secondary bacterial  infection 
2) Postinflammatory    hyperpigmenta- tion  and hypopigmentation 
3) Onychodystrophy and onycholysis 
4) Excoriations 
5)  Other 
f. Other 
 
B.  Diagnostic  tests 
I. Potassium  hydroxide  preparation  (KOH) 
 Materials is obtained from the site of infection. If the lesion  is a pustule,  the 
purulent material  can  be used  for the  specimen.   In cases of cutaneous  involvement, the 
specimen can be obtained from the edge of a lesion. The material is placed on a glass slide 
and   1 0%  to  20%  KOH  is  added  with  or without  dimethyl  sulfoxide. A fungal stain, 
such  as  Chlorazol   Black  E,  or  Parker's blue  black  ink  may  be  used  to  highlight the  
pseudohyphae.  The  presence  of pseudohyphae and  yeast  forms  confirm  infection 
 2.. Fungal  culture 
 Candida  species   are  yeasts   rather   than molds and therefore  grow as yeast 
colonies on Sabouraud's glucose  agar. The addition of cycloheximide to Sabouraud's agar 
may inhibit many  species of Candida and other saprophytes.    However,  C.  albicans   will 
grow  on media  containing cycloheximide. Examples of such media include Mycosel, 
Mycobiotic,  and   dermatophyte  test  medium.  Although  C. albicans  will grow  on 
dermatophyte test media, the agar will not exhibit a red  color  change  as occurs with 
dermatophyte growth  if read  at the appropriate time interval, as indicated by the 
manufacturer's instructions. 
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TREATMENT
22,24 
Oral Candidiasis 
 Topical azoles (clotrimazole troches),  
Oral azoles (fluconazole, ketoconazole, or itraconazole), or  
Oral polyenes  (such  as  nystatin (oral candidiasis in infants, Nystatin suspension [100, 000 
units/ml] dropped into the mouth at 4-6 hour intervals or after each feed is usually used)  or  oral   
amphotericin  B). 
 
Vulvovaginal candidiasis 
 
Topical agents including azoles (all are used for 1 to 7 days depending on risk 
classification: over-the counter (OTC)  clotrimazole,  OTC  butoconazole,  OTC miconazole, 
OTC tioconazole, terconazole), nystatin [100,000 U per day for 7 to 14 days], oral azoles 
(ketoconazole (400 mg for five days), which is not approved in the United States); itraconazole 
(200 mg for 1 day, or 200 mg per day for three days), which is not approved in the United 
States; and fluconazole (150 mg). 
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NYSTATIN 
Structural formula 
                                                           
 
CAS Number
61
 
 1400-61-9
 
Synonyms
25 
 Mycostatin, Nistatina,NYS,Nystatin, Nystatine and Nystatinum. 
Empirical formula
25 
 C47H75NO17 
Chemical name
25 
 (21E,23E,25E,27E,31E,33E)-20-{[(3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-
4,6,8,11,12,16,18,36-octahydroxy-35,37,38-trimethyl-2,14-dioxo-1-oxacyclooctatriaconta-
21,23,25,27,31,33-hexaene-17-carboxylic acid 
Molecular weight
61   : 926.1 
Description
61,62 
 Nature : A Yellow to slightly brown powder, Hygroscopic. 
 Odour  : Characteristic. 
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Solubility        :  Freely soluble in Dimethylformamide and Dimethyl sulphoxide. 
Slightly soluble in Methanol,Very slightly soluble in water, insoluble in 
chloroform, in ether, and in Ethanol (95%). 
   pH : 6.5 to 8, determined in a 3.0 percent w/v. 
  Melting point : 130˚C 
 
 
Mechanism of action
25 
 Nystatin exerts its antifungal activity by binding to ergosterol found in fungal cell 
membranes. Binding to ergosterol causes the formation of pores in the membrane. Potassium and 
other cellular constituents leak from the pores causing cell death. The figure   :shows the 
Mechanism of action Nystatin with the example of Amphotericin B. 
 
Figure-11:  Mechanism of action.
57 
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Pharmacokinetics
26 
Gastrointestinal absorption of Nystatin is insignificant. Most orally administered Nystatin 
is passed unchanged in the stool. In patients with renal insufficiency receiving oral therapy with 
conventional dosage forms, significant plasma concentrations of Nystatin may occasionally 
occur. Onset of action is rapid, Unknown peak and Half-life, Duration of action  for 6-12 hours.
59 
 
Therapeutic indications
26 
 Nystatin(topical powder, cream and ointment) is indicated in the treatment of cutaneous 
or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida 
species. 
Dosage and administration
26 
 Usual Adult Dose for Cutaneous Candidiasis 
Apply nystatin topical cream, ointment or powder in a quantity sufficient to cover the 
affected area and immediately surrounding skin 2 to 4 times a day. 
 
The powder formulation is useful for the treatment of moist areas or lesions. 
 
Therapy should be continued for 2 to 8 weeks, depending on the nature and severity of the 
infection. 
 Usual Adult Dose for Vaginal Candidiasis 
Insert one Nystatin vaginal tablet (100,000 units) vaginally once a day, preferably at 
bedtime, for a total of 14 days. 
Usual Pediatric Dose for Cutaneous Candidiasis 
Apply Nystatin topical cream, ointment or powder in a quantity sufficient to cover 
the affected area and immediately surrounding skin 2 to 4 times a day. 
 
The powder formulation is useful for the treatment of moist areas or lesions. 
 
Therapy should be continued for 2 to 8 weeks, depending on the nature and severity of 
the infection. 
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Usual Pediatric Dose for Vaginal Candidiasis 
>13 <18 years: Insert one nystatin vaginal tablet (100,000 units) vaginally once a day, 
preferably at bedtime, for a total of 14 days. 
Other Comments 
For fungal infections of the feet caused by Candida, dust the powder freely on the feet as 
well as in shoes and socks. 
The vaginal tablets should be used continuously, regardless of initiation of menses. 
For external use only. Avoid contact with the eyes. 
Contraindication
26 
The preparation is contraindicated in patients with a history of hypersensitivity to any of 
its components.
 
Drug interactions
26 
 Minor drug interaction with Vitamins only 
Side effects
26 
Nystatin is well tolerated even with prolonged therapy. Oral irritation and sensitization 
have been reported.  
Nystatin vaginal tablets have included vaginal irritation, burning, and itching. At least 
one case of severe vulvovaginitis has also been reported. 
Gastrointestinal: Diarrhea (including one case of bloody diarrhea), nausea, vomiting, 
gastrointestinal upset/disturbances. 
Dermatologic: Rash, including urticaria , Skin irritation, burning, itching, eczema, and pain on 
application in less than 0.1% of patients. Stevens-Johnson syndrome has been reported very 
rarely. 
Other: Tachycardia, bronchospasm, facial swelling, and non-specific myalgia have also been 
rarely reported. 
Hypersensitivity
26 
Hypersensitivity side effects associated with Nystatin topical powder, 
cream, and ointment have included allergic reactions and allergic contact dermatitis in less than 
0.1% of patients.
 
Storage
62 
In an airtight container , protected from light.                                                                                    
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ETHYL CELLULOSE
79 
Structural formula 
 
Nonproprietary names 
BP –Ethylcellulose 
PhEur -Ethylcellulose 
             USP-NF-Ethylcellulose 
Synonyms 
 Aquacoat ECD; Aqualon; Ashacel; E462; Ethocel; ethylcellulosum;Surelease.
 
 
Empirical formula 
 C12H23O6(C12H22O5)nC12H23O5. 
Chemical name 
 Cellulose ethyl ether  
CAS Number 
 [9004-57-3]
 
Molecular weight 
Description 
Ethylcellulose is a tasteless, free-flowing, white to light tan-colored 
powder. 
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Solubility     
 Ethylcellulose is practically insoluble in glycerin, propylene glycol, and water. 
 Ethylcellulose that contains less than 46.5% of ethoxyl groups is freely soluble in 
chloroform,methyl acetate, and tetrahydrofuran, and in mixtures ofaromatic hydrocarbons with ethanol 
(95%). 
Ethylcellulose that contains not less than 46.5% of ethoxyl groups is freelysoluble in 
chloroform, ethanol (95%), ethyl acetate, methanol,and toluene. 
 
Stability and Storage Conditions 
 Ethylcellulose is a stable, slightly hygroscopic material. It ischemically resistant to 
alkalis, both dilute and concentrated, andto salt solutions, although it is more sensitive to acidic 
materialsthan are cellulose esters. 
Ethylcellulose is subject to oxidative degradation in the presence of sunlight or UV light 
at elevated temperatures. This may beprevented by the use of antioxidant and chemical additives 
thatabsorb light in the 230–340 nm range. 
Ethylcellulose should be stored at a temperature not exceeding32˚C (90˚F) in a dry area 
away from all sources of heat. It shouldnot be stored next to peroxides or other oxidizing agents. 
 
Incompatibility 
Incompatible with paraffin wax and microcrystalline wax. 
Application 
 Ethylcellulose is widely used in oral and topical pharmaceutical 
 Hydrophobic coating agent for tablets and granules. 
 High-viscosity grades of ethylcellulose are used in drug microencapsulation. 
 Used as Binder 
Ethylcellulose is used as a thickening agent in creams, lotions, or gels 
 Ethylcellulose has been studied as a stabilizer for emulsions. 
 Microencapsulation 10.0–20.0 % 
Sustained-release tablet coating 3.0–20.0% 
Tablet coating 1.0–3.0 % 
Tablet granulation 1.0–3.0% 
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POLYMETHYL METHACRYLATE
79 
 
Structural formula 
     
 
Synonyms 
 Methyl methacrylate polymer,PMMA. 
 
Empirical formula 
 (C5H8O2)n 
Description 
 Transparent Crystals, odourless. 
Functional Category 
Film-forming agent, tablet binder, tablet diluent. 
Application 
 Depending upon the ratios use may vary 
 Polymethacrylates are primarily used in oral capsule and tablet formulations as 
film-coating agents 
 Eudragit RL, RS, NE 30 D, NE 40 D, and NM 30 D are used toform water-
insoluble film coats for sustained release products. 
  Solid polymers may be used in direct-compression processes in quantities of 10–
50%. 
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 Polymethacrylate polymers may additionally be used to form the matrix layers of 
transdermal delivery systems and have also beenused to prepare novel gel 
formulations for rectal administration. 
POLYVINYL ALCOHOL
79 
 
Structure 
 
Synonyms 
Airvol; Alcotex; Elvanol; Gelvatol; Gohsenol; Lemol; Mowiol,Polyvinol; PVA; vinyl 
alcohol polymer. 
 
Empirical formula 
(C2H4O)n 
  
Molecular weight 
 Commercially available grades of polyvinyl acohol. 
 
High viscosity -200 000 
 Medium viscosity -130 000 
Low viscosity -20 000 
Functional category 
Coating agent; lubricant; stabilizing agent; viscosity-increasingagent. 
Description 
 Polyvinyl alcohol occurs as an odorless, white to cream-coloredgranular powder. 
Properties 
 Melting point: 228˚C for fully hydrolyzed grades; 
180–190˚C for partially hydrolyzed grades. 
 Solubility   : soluble in water; slightly soluble in ethanol (95%);insoluble in organic                     
EXCIPIENTS PROFILE 
 
Department of Pharmaceutics, Madres Medical College Page 57 
 
solvents. Dissolution requires dispersion (wetting) of the solid in water at  
room temperaturefollowed by heating the mixture to about 90˚C for approximately   
5 minutes.   Mixing  should be continuedwhile the heated solution is cooled to room temperature. 
 
Stability andstorage conditions 
 Polyvinyl alcohol is stable when stored in a tightly sealedcontainer in a cool, dry place.  
 Aqueous solutions are stable incorrosion-resistant sealed containers. Preservatives 
maybeadded to the solution if extended storage is required. 
  Polyvinyl alcohol undergoes slow degradation at 100˚C and rapid degradation at 
200˚C; it is stable on exposure to light. 
Safety 
 Polyvinyl alcohol is generally considered a nontoxic material. Itis nonirritant to the skin   
and eyes at concentrations up to 10%;concentrations up to 7% are used in cosmetics. 
 
Regulatory status 
 Included in the FDA Inactive Ingredients Guide (ophthalmicpreparations and oral 
tablets).Included in nonparenteralmedicines licensed in the UK.Included in the Canadian List of 
Acceptable Non-medicinal Ingredients. 
Application 
 Polyvinyl alcohol is used primarily in topical pharmaceutical and ophthalmic 
formulation. 
 It is used as a stabilizing agent for emulsions (0.25–3.0% w/v). 
 Polyvinyl alcohol is also usedas a viscosity-increasing agent for viscous 
formulations such as ophthalmic products. 
  It is used in artificial tears and contact lens solutions for lubrication purposes. 
 Used in sustained-release formulations for oral administration,and in transdermal 
patches. 
 Polyvinyl alcohol may be made into microspheres when mixed with a 
glutaraldehyde solution. 
Used in Emulsions   -0.5 % concentration, 
 Ophthalmic formulations - 0.25–3.00% concentration , 
Topical lotions- 2.5% concentration. 
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CARBOMER (CARBOPOL 934 )
79 
Structure 
 
Synonyms  
 Acrypol; Acritamer; acrylic acid polymer; carbomera; Carbopol;carboxypolymethylene; 
polyacrylic acid; carboxyvinyl polymer;Pemulen; TegoCarbomer. 
 
Empirical formula 
 (C3H4O2) n 
Molecular weight 
 The molecular weight of carbomer is theoretically estimated at 7 – 105to 4 -109 
 
Functional category 
 Bioadhesive material; controlled-release agent; emulsifying agent;emulsion stabilizer; 
rheology modifier; stabilizing agent; suspending agent; tablet binder. 
 
Description 
 Carbomers are white-colored, ‘fluffy’, acidic, hygroscopic powderswith a characteristic 
slight odor. 
Properties 
 Melting Point:Decomposition occurs within 30 minutes at 260˚C. 
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Safety 
 Carbomers are used extensively in non parenteral products, particularly topical 
liquid and semisolid preparations.  
 Grades polymerized in ethyl acetate may also be used in oral formulations. 
 There is no evidence of systemic absorption of carbomer polymers following oral 
administration. 
 Acute oral toxicity studies in animals indicate that carbomer 934P has a loworal 
toxicity, with doses up to 8 g/kg being administered to dogswithout fatalities 
occurring. 
 Carbomers are generally regarded as essentially nontoxic and nonirritant 
materials,there is no evidence in humans of hypersensitivity reactions to 
carbomers used topically. 
 
Stability andstorage conditions 
 Carbomers are stable, hygroscopic materials that may be heated attemperatures 
below 104˚C for up to 2 hours without affecting theirthickening efficiency.  
 Carbomer powder should be stored in an airtight, corrosionresistantcontainer and 
protected from moisture. The use of glass, plastic, or resin-linedcontainers is 
recommended for the storage of formulations containing carbomer. 
 
Regulatory status 
 Included in the FDA Inactive Ingredients Database (oral suspensions, tablets; 
ophthalmic, rectal, topical, transdermal preparations;vaginal suppositories).  
 Included in non parenteral medicines licensed in Europe. Included in the 
Canadian List of Acceptable Nonmedicinal Ingredients. 
Application 
 
 In tablet formulations, carbomers are used as controlled release agents and/or as 
binders. 
  Higher viscosity does not result in slower drug release with carbomers. 
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Uesd as Emulsifying agent -0.1–0.5 % 
Gelling agent         -0.5–2.0 % 
Suspending agent   - 0.5–1.0 % 
Tablet binder          -0.75–3.0 % 
Controlled-release agent- 5.0–30.0 % 
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                      The List of excipients used and their Manufacturers are in the Table : 5. 
 
                                                  Table-5   : List of Materials Used 
 
S.No. DRUG/EXCIPIENTS MANUFACTURER 
1. Nystatin  Caplin point Laboratories Pvt Ltd. 
2. Ethyl cellulose Caplin point Laboratories Pvt Ltd. 
3. Polymethyl methacrylate Lab chemicals. 
4. Polyvinyl alcohol Lab chemicals. 
5. Dichloromethane Chen chems labs. 
6. Dimethyl sulfoxide Chen chems labs. 
7. Potassium dihydrogen ortho phosphate Supra chemicals, Chennai. 
 
8. Disodium hydrogen ortho phosphate Supra chemicals, Chennai. 
 
9. Methanol Sisco research laboratories Pvt Ltd. 
10. Dialysis Bag (LA653) Hi media Lab, Mumbai. 
11. Carbopol 934 Sai Mirra Innopharm Pvt. Ltd. 
 
12. Glycerin Microlabs Pvt. Ltd.  
13. Triethanolamine Microlabs Pvt. Ltd. 
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The List of Equipments used in the study and their Manufacturer are in Table- 6 
Table-6   :  List of Equipments Used. 
S.No EQUIPMENTS MANUFACTURER 
1. High Speed Homogenizer Remi,Vasai. 
2. Ultra sonicator Lark. 
3. Electronic balance McDalal,, Chennai. 
4. Magnetic Stirrer with Hot plate Remi,Vasai. 
5. UV-Visible Spectrophotometer Shimadzu,Japan. 
6. High speed cooling centrifuge Remi,Vasai. 
7. Binocular microscope Olimpus. 
8. Malvern Zeta Sizer Malvern,Germany. 
9. Scanning electron microscope Hitachi,Japan. 
10. FT-IR Spectrophotometer Nicolet,India. 
11. pH meter Symchrony.India. 
12. Freeze dryer McDalal,, Chennai. 
13. Hot air oven McDalal,, Chennai. 
14. Stability Chamber Remi CHM 6+. 
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METHODOLOGY 
COMPATIBILITY STUDIES FOR DRUG AND EXCIPIENTS
28
 
For the development of formulation dosage form, preformulation studies were carried out to 
confirm no interaction  between the drug and excipients. It gives information needed for selection of 
excipients with the drug for the formulation of Nanosponge. Physical compatibility of the drug with 
excipients were done. The possibility of drug excipients (Ethyl cellulose and Polymethyl 
methacrylate) interaction were investigated by FT-IR Spectrum study. 
Physical Compatibility 
 Physical compatibility of the drug and excipients were carried at Room 
temperature and at 40˚C±2˚C/75±5%RH(in days) with the physical admixture of drug and 
excipients. 
Fourier Transforms Infrared (FT-IR)Spectroscopic studies 
The spectroscopic studies were carried out to find out the interaction between pure 
drug, excipients and its physical mixture by KBr pellet technique using FT-IR 
spectrophotometer. The IR spectrum of the physical mixture is then compared with the 
spectrum of pure drug(Nystatin)to assess the compatibility of the excipients and drug. The 
scanning range is 450-4000 cm
-1
and the resolution is 4cm
-1
. 
 PREPARATION OF PHOSPHATE BUFFER pH 5.5
69 
 Solution I –  13.612 g of Potassium dihydrogen phosphate in 1000 ml of Distilled 
Water. 
 Solution II – 35.08 g of Disodium hydrogen phosphate in 1000 ml of Distilled Water. 
 96.4 ml of Solution I and 3.6 ml of Solution II were mixed together. 
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STANDARD CURVE OF NYSTATIN
28,29 
 100mg of drug was accurately weighed and dissolved in 30 ml methanol and made 
up to 100ml with phosphate buffer pH 5.5. Calibration curve was prepared in a mixture of 
phosphate buffer and methanol (7:3) at λ max 305 nm. 
FORMULATIONDEVELOPMENT 
FORMULATION OF NYSTATIN LOADED NANOSPONGE
30 
 Nystatin Nanosponges were prepared by Emulsion solvent evaporation method. Two 
different polymers were used in the formulation. Ethyl cellulose (EC) and Polymethyl 
methacrylate (PMMA) were the Polymers used. Polyvinyl alcohol in Distilled water is 
used as the aqueous phase. The Drug is dissolved in the required solvent (Dimethyl 
sulphoxide) and the Polymers (1:1, 1:2, 1:3, 1:4, and 1:5) were dissolved in 
Dichloromethane. The Drug solution was poured into the polymer solution and the mixture 
was shaken well. Then the Drug polymer mixture was poured into the aqueous phase and 
the mixer is subjected to homogenization using High speed homogenizer in 1500 rpm for 2 
hours at 35˚C.The formed Nanosponges were centrifuged by high speed cooling centrifuge 
and the residue was freeze dried. 
Table-7    : Formulation of Nanosponge 
S.No INGREDIENTS F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
1. Drug ( mg) 100 100 100 100 100 100 100 100 100 100 
2. EC( mg) 100 200 300 400 500    -    -    -    -    - 
3. PMMA ( mg)    -      -    -    -    - 100 200 300 400 500 
4. PVA (g) 0.2 0.2 0.2 0.2 0.2 0.3 0.3 0.3 0.3 0.3 
5. DCM ( ml) 20 20 20 20 20 20 20 20 20 20 
6. Distilled 
water(ml) 
100 100 100 100 100 100 100 100 100 100 
 
EC-Ethyl cellulose, PMMA – Polymethyl methacrylate, DCM – Dichloromethane, PVA-
Polyvinyl Alcohol. 
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Figure-11. Schematic Representation of Preparation of Nanosponge 
    CHARACTERIZATION OF NYSTATIN LOADED NANOSPONGE 
All the formulated Nystatin loaded Nanosponge were evaluated for its 
Drug content, entrapment efficiency, particle size distribution, polydispersity index ,in vitro 
drug release and kinetics of drug release. 
Determination of drug content
31
 
The total drug content of Nanosponge was determined by spectrophotometric 
analysis.10milligramequivalentof Nystatin loaded Nanosponge taken in a beaker(closed to 
avoid evaporation) containing (10 ml)of Methanol and stirred for 30 minutes in magnetic 
stirrer, 3ml of that solution is pipetted out and that volume was made upto10ml by using 
pH5.5phosphatebuffer to make1µg/ml concentration. The absorbance was measured at 
305nm λmax  using UV spectrophotometer. From the absorbance  drug content was 
calculated. 
The percentage Drug Content is calculated by  following formula: 
                                                     Practical Drug Content 
                %Drug content  =     ---------------------------------     x 100 
                                                    Theoretical drug content 
 
 
Aqueous 
phase 
Organic 
phase 
Solvent 
evaporation 
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 Determination of drug entrapment efficiency
28 
 The entrapment efficiency was determined by measuring the concentration of the 
drug in the supernatant after centrifugation. The unentrapped Nystatin were determined 
by adding 10 mg Nystatin loaded Nanosponge in 10 ml of methanol and then the 
dispersion were centrifuged at 9,000rpm for 30 minutes at 4ºC using a cooling centrifuge 
in order to separate entrapped from the unentrapped drug. The free drug concentration in 
supernatant layer after centrifugation is determined at λmax(305nm) using UV 
Spectrophotometer 
 
The percentage entrapment efficiency(%EE) is calculated by following formula: 
 
                        Weight of Initial drug- Weight of  free drug 
%EE=   ------------------------------------------------------------------X  100. 
                                     Weight of Initial drug 
in- vitro releasestudies
28 
 The in vitro release of Nystatin from Nanosponge was evaluated by the Dialysis Bag 
diffusion technique. The release studies of Nystatin from Nanosponge were performed in 
Phosphate buffer of pH5.5 and methanol (70:30)  18mg equivalent Nystatin Nanosponge 
were suspended in 10 ml of buffer pH 5.5 mixture and placed in the dialysis bag(donor 
compartment) and sealed at both ends. The dialysis bag were immersed in receptor 
compartment containing 100ml of buffer mixture, which was stirred at 100 rpm and maintain 
32 ± 2˚C. The receptor compartment was covered to prevent evaporation of the diffusion 
medium. Samples were taken from the receptor compartment and the same amount were 
replaced with the diffusion medium. Samples are taken upto 24hrs. Nystatin in the samples 
were measured spectrophotometrically at λ 305nm. 
 Same procedure was carried out for Pure drug and in vitro release were measured 
spectrophotometrically at λ 305nm. 
 SELECTION AND EVALUATION OFOPTIMIZEDFORMULATION 
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The best formulation selection based on the results obtained from particle size, 
entrapment efficiency, in-vitro release studies and kinetics of drug release. 
 FT-IR spectroscopicstudies  
The compatibility study was carried out for optimized formulations(F3 and F7) using 
FTIR at wavelength range of 4000to400cm
-1
.Spectrum for optimized formulation were taken 
and compared. 
Morphology ofNanosponge by scanning electronmicroscopy (SEM) technique
32 
The Surface Morphology of the Nanosponge can be measured by SEM. The 
formulations are poured in a circular aluminum stubs using double adhesive tape, and coated 
with gold in HUS– 5GB vaccum evaporator and observed in Hitachi S– 3000N SEM at an 
acceleration voltage of 10 Kv and a magnification of5000X. 
Particle size distribution
33
: 
 Particlesize (z-averagediameter), and polydispersity index (as a measure of the width 
of the particle size distribution)of Nystatin loaded Nanosponge dispersion is performed by 
dynamic light scattering also known as photon correlation spectroscopy(PCS) using a 
Malvern Zeta sizer 3000NanoS(Malvern instruments, UK) at 25°C. 
Prior to measurements all samples were diluted using ultra–purified water to yield a 
suitable scattering intensity. The diluted nanosponge dispersion was poured into disposable 
sizing cuvette which is then placed in the cuvette holder of the instrument and analyzed. Air 
bubbles were removed from the capillary before measurement. 
 Kinetics of drug release
78
. 
To analyze the drug release mechanism, in-vitro release are fitted into a 
 
 Zero-order 
 First order 
 Higuchi, 
 Hixon-Crowell cube root law, 
 Korsmeyer- peppas model. 
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1/3 =  κt 
The zero order rate describes the systems where the drug release rate is 
independent of its concentration. It is ideal for the formulation to have release profile 
of zero order to achieve pharmacological prolonged action. 
                                                               Qt= Q0+ K0t 
Where, Qtis the amount of drug dissolved in time t, 
Q0is the initial amount of drug in the solution (most times, Q0=0)and 
K0 is the zero order release constant expressed in units of concentration/time. 
The first order rate describes the release from a system where the release rate is 
Concentration  dependent. 
                                                           log C = log C0–kt/ 2.303 
Where, C is the concentration of the drug at time(t), 
C0 is the initial concentration of the drug and  
k is the first-order release rate constant. 
Higuchi described the release of drugs from porous, insoluble matrix as a square 
root of time dependent process based on Fickian diffusion. 
                                                         Q = kt
1/2 
Where Q is the amount of drug released in time t. 
k constant reflecting design variable system (Differential rate constant) and 
t Time in hours 
Hixson and Crowell recognized that the particles diameter and regular area is proportional  
to the cube root of its volume. 
                                                      W0
1/3 –Wt
 
Where W0 is the initial amount of drug in the pharmaceutical dosage form, 
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Wtis the remaining amount of drug in the pharmaceutical dosage form at time t and 
κ(kappa) is a constant incorporating the surface-volume relation. 
 
Korsmeyer–Peppas describes  the fraction of drug release relates exponentially 
with respect to time. 
                                                                       Mt/ M∞= Kt
n
 
Where Mt /M∞ is a fraction of drug released at time t, 
K is the release rate constant and n is the release exponent. 
n is  diffusional exponent indicative of the mechanism of the drug release. 
The diffusion mechanism is given by the slope (n) value, 
                                                   Table -8: diffusion mechanism 
n value Mechanism 
0.45 Fickian diffusion 
0.45˂ n˂ 0.89 Anamolous or non-Fickian diffusion 
0.89 Case-II transport 
n˃ 0.89 Super case -II transport 
 
 The models were used to analyze the release of pharmaceutical polymeric dosage 
forms when the release mechanism was not known or more than one type of release was 
involved, the r
2 
and K values were calculated for the linear curve obtained by regression 
analysis of the above plots. 
STABILITY STUDIES 
 The stability studies of the optimized Nanosponge were performed at different 
conditions of temperature and the effect on physical characteristic, entrapment efficiency 
and drug content was noted. The Nanosponge were kept in the airtight container and stored 
at 40±2˚C and in Relative humidity 75±5% for 45 days. The samples were analyzed for the 
above parameter in 15days,30 days and 45days. 
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 The samples were withdrawn on 15 days, 30days and 45days and checked for 
changes in Physical appearance and drug content as per ICH QIA (R2) guidelines. 
                                       Table-9 : ICH guidelines ICH QIA (R2)
38 
Study Storage condition Minimum time period 
covered by data at 
submission 
Long term
* 25˚C/60% RH ± 5% or 30°C ± 
2°C/65% RH ± 5% RH 
12 months 
Intermediate
** 
30°C ± 2°C/65% RH ± 5% RH 6 months 
Accelerated 40°C ± 2°C/75% RH ± 5% RH 6 months 
*It is up to the applicant to decide whether long term stability studies are performed 
at 25 ± 2°C/60% RH ± 5% RH or 30°C ± 2°C/65% RH ± 5% RH.   
 
**If 30°C ± 2°C/65% RH ± 5% RH is the long-term condition, there is no intermediate 
condition. 
 
FORMULATION OF NYSTATIN LOADED NANOSPONGE GEL
74,75 
The formulation of Nanosponge prepared using the optimized ratio of Polymer 
containing Nystatin equivalent to18mg was incorporated into the gel base composed of 
Carbopol 934 (1%), Glycerol (15%), Triethanolamine (q.s.) and distilled water up to 1g. 
Table-10: Preparation of Gel 
S.No. INGREDIENTS GEL BASE  
1. Carbapol 934 1 % 
2. Glycerol 15 % 
3. Triethanolamine Quantity Sufficient 
4. Distilled water Upto 15g 
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EVALUATION OF NANOSPONGE GEL 
Physical Appearance 
The prepared gel was examined for clarity, color, homogeneity and the presence of 
foreign particles. 
        pH 
2.5g of gel was accurately weighed and dispersed in 25 ml of distilled water. The pH of 
the dispersion was measured by using a digital pH meter. 
Rheological study 
Viscosity measurement:  
Viscosity was determined by Brookfield viscometer. In the present study, spindle 
no. S64 with an optimum speed of 0.6 rpm was used to measure the viscosity of the 
preparation. 
Content Uniformity: 
The drug content of the prepared gel was carried out by dissolving accurately weighed 
quantity of gel equivalent to 9mg of the drug in a beaker containing 10 ml of methanol, 
stir  the solution for 30 minutes and centrifuged in High speed cooling centrifuge and 3ml 
of the solution is made upto 10 ml with  phosphate buffer pH 5.5. The samples were 
analyzed spectrophotometrically at λmax 305 nm against blank using UV- Visible 
spectrophotometer.   
     In-vitroDrug Diffusion study 
In- vitro drug diffusion study was studied using dialysis bag. The Nanosponge gel 
equivalent to 18mg of the drug was placed in a Dialysis Bag having 8 cm length and 3 cm 
breath, both the sides are tied with thread. This acted as the donor compartment. Then the 
bag was placed in a beaker containing 100 ml phosphate buffered methanol pH 5.5, which 
acted as receptor compartment. The temperature of the receptor medium was maintained 
at 37°±2°C and the medium was stirred at a speed of 100 rpm using a magnetic stirrer. 
5 ml of the samples were collected at a predetermined time and replenished 
immediately with the same volume of fresh buffer PB mixture pH5.5. The sink condition 
     8.MATERIALS AND METHODS 
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was maintained throughout the experiment. The collected samples were analyzed 
Spectrophotometrically at  305 nm using UV- Visible spectrophotometer. 
MICROBIOLOGICAL STUDY
 49
  
  Antifungal activity for the prepared Nanosponge gel were carried out. Candida 
albicans was grown in Malt Extract Agar,(MAE) with medium composition: malt extract 17 
g/L and agar 20g/L. 
  The assay was done using the agar well diffusion method. Sterile agar plates were 
prepared by pouring the sterilized media in sterile Petri dishes under aseptic conditions.1 
mm of the test organism was spread on agar plates. Using a sterile tube with a diameter of 
6mm, the wells were made according to the number of samples. The wells were inoculated 
with 80μL of sample. The antimicrobial activity was interpreted based on the size of 
inhibition zone (IZ) diameter, which was measured in mm from observation of clear zones 
surrounding the wells. 
 
 
 
RESULTS AND DISCUSSION 
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PRE-FORMULATION STUDIES 
The optimization of a formulation can be done only after a thorough investigation of 
its physic chemical properties of the drug and excipients. The drug and the polymer must be 
compatible for a successful formulation. 
Physical Compatability  
Table-11:Physical compatability 
 
 
S.No. 
Description and condition 
Drug (D)    
and  
excipients 
Initial Room 
temperature (in 
days) 
40˚C±2˚C/75±5% 
RH(in days) 
10 20 30 10 20 30 
1. Drug NC NC NC NC NC NC NC 
2. D+EC NC NC NC NC NC NC NC 
3. D+PMMA NC NC NC NC NC NC NC 
4. D+PVA NC NC NC NC NC NC NC 
      NC – No Change. 
 Inference 
 The drug and the excipients of the formulation are physically compatible with each 
other. They were evaluated for 10, 20 and  30 days at room temperature and at 
40˚C±2˚C/75±5% Relative Humidity. 
Chemical compatability 
   FT-IR spectroscopy gives the possible information about the interaction between the 
drug and Polymer. 
Drug-Polymer compatibility studies 
FT-IR Spectroscopicstudies 
The  compatibility  between  drug  and  Polymer was confirmed using  FT-IR 
Spectroscopy. Infrared spectroscopic analysis for drug (Nystatin),Polymer, Drug-Polymer 
admixture was carried out. 
RESULTS AND DISCUSSION 
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                                   Figure-12 :FT-IR Spectrum of Nystatin. 
                                    Table-12 :FT-IR Data of Nystatin. 
 
 
Inference 
 The peak shows the presence of NH,OH, aromatic CH, aliphatic CH and Carboxylic 
C=O groups in the Nystatin sample. 
 
S.No. Peak absorbed at 
Wave number cm
-1 
Characteristics 
1. 3787.90  OH- Stretching 
2. 3402.18 NH -Stretching 
3. 3008.73 Aromatic CH- Stretching 
4. 2923.87 Aliphatic CH- Stretching 
5. 1627.80 Carboxylic C=O - Stretching 
RESULTS AND DISCUSSION 
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                                   Figure-13  :FT-IR Spectrum of Ethyl cellulose. 
                                    Table-13::FT-IR Data of Ethyl cellulose. 
                                     
 
Inference 
 The peak shoes that the Ethyl cellulose has Characteristics Aliphatic CH and 
Methyl CH – streching. 
 
S.No. 
Peak absorbed at 
Wave number cm
-1 
Characteristics 
1. 2977.87 Aliphatic CH - Stretching 
2. 1635.52 CH(methyl)-Stretching 
RESULTS AND DISCUSSION 
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Figure-14 :FT-IR Spectrum of Polymethyl methacrylate. 
Table-14 :FT-IR Data of Polymethyl methacrylate. 
       Inference 
 The peak shows that the Characteristics C=O, Aliphatic CH and Methyl CH –
stretching. 
 
S.No. Peak absorbed at 
Wave number cm
-1 
Characteristics 
1. 1735.81 C=O - Stretching 
2. 2923.87 Aliphatic CH -Stretching 
3. 1535.22 CH (methyl)- Stretching 
RESULTS AND DISCUSSION 
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                                   Figure-15  :FT-IR Spectrum of Nystatin with PMMA. 
                                      Table-15  :FT-IR Data of Nystatin with PMMA 
 
S.No. 
Peak absorbed at 
Wave number cm
-1 
Characteristics 
1. 3787.92 OH -Stretching 
2 3433.04 NH- Stretching 
3. 3001.02 Aromatic CH- Stretching 
4. 2954.73 Aliphatic CH- Stretching 
5. 2854.44 Carboxylic OH - Stretching 
6. 1735.81 C=O- Stretching 
 
 Inference 
 The peak observed in the FTIR Spectrum of Nystatin pure drug with 
Polymer(PMMA) showed no shift and no disappearance of characteristic peaks of pure 
drug suggesting no interaction between the drug and Polymer. 
RESULTS AND DISCUSSION 
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Figure-16 :FT-IR Spectrum of Nystatin with Ethylcellulose 
Table-16 :FT-IR Data of Nystatin with Ethylcellulose. 
S.No. 
Peak absorbed at 
Wave number cm
-1 Characteristics 
1. 3787 OH -Stretching 
2 3400 NH- Stretching 
3. 2954 Aliphatic CH- Stretching 
4. 1700 Carboxylic OH - Stretching 
Inference 
 The peak observed in the FTIR Spectrum of Nystatin pure drug with Polymer (Ethyl 
cellulose) showed no shift and no disappearance of characteristic peaks of pure drug 
suggesting no interaction between the drug and Polymer
29
. 
RESULTS AND DISCUSSION 
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 STANDARD CURVE OFNYSTATIN 
 The UV spectrometric method was used to analyse Nystatin. The absorbance of the 
drug in phosphate buffered methanol pH 5.5.  (70:30) was measured at a wavelength of 
305 nm. The results are given in the Table and Figure 
Table-17 :Data for calibrationcurve 
S.No Concentration (mcg/ml) Absorbanceat305 nm 
1
. 
0 0 
2
. 
2 0.148 ± 0.010 
3
. 
4 0.293 ± 0.0086 
4
. 
6 0.445 ± 0.026 
5
. 
8 0.586 ± 0.0061 
6
. 
10 0.756 ± 0.0214 
 
 
 
Figure-17   : Calibration curve for Nystatin. 
Inference 
                        It  was  found that  the solutions of N y s t a t i n  in Phosphate buffered 
methanol pH5.5 show linearity  (R
2
=0.999) in absorbance at concentrations of 2-10 mcg/ml 
and obey  Beer Lambert’s law 77. 
y = 0.0749x - 0.0034 
R² = 0.9994 
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FORMULATION OFNYSTATIN NANOSPONGE 
Nystatin Nanosponge were prepared by  homogenization technique followed by 
centrifugation. 
 
 
 
Figure-18 :   Formulation of Nanosponges 
 
 
 
 
 
 
 
 
RESULTS AND DISCUSSION 
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CHARACTERIZATION OF NANOSPONGE 
Drug content and entrapment Efficiency  
Table-18 : Drug content and Entrapment Efficiency of NystatinNanosponge 
 
 
 
 
 
 
 
 
 
 
 
FORMULATION 
CODE 
%DRUG CONTENT 
(%w/v) 
%ENTRAPMENT         
EFFICIENCY (% w/v) 
F1 94.52±0.109 98.79 
F2 91.31±0.633 98.14 
F3 90.26±0.266 98.94 
F4 92.54±1.173 98.86 
F5 82.90±1.239 97.85 
F6 90.36±0.366 96.57 
F7 95.714±0.231 99.21 
F8 85.44±0.555 85.44 
F9 88.95±0.524 88.95 
F10 86.70±0.708 86.70 
RESULTS AND DISCUSSION 
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DRUG CONTENT 
 
 
  Figure-19 : % Drug content of NystatinNanosponge 
Inference 
The Drug content of the formulations was observed to be between 82.90 to 95.71.                         
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ENTRAPMENTEFFICIENCY 
 
 
               Figure-20 :% Entrapment Efficiency of NystatinNanosponge 
Inference 
The entrapment efficiency was found to be 97.85 to 99.21. The highest entrapment 
efficiency was observed with 99.21 and 98.94 for the formulations  F3 and F7.    
 
 
 
 
 
 
75
80
85
90
95
100
105
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10
IN
 %
 
FORMULATION 
% ENTRAPMENT EFFICIENCY 
Series1
RESULTS AND DISCUSSION 
Department of Pharmaceutics, Madras Medical College Page 84 
 
SURFACE MORPHOLOGY OF NANOSPONGE 
Surface morphology of Nanosponge was measured by Scanning Electron 
Microscopy (SEM). 
 
                                      Figure-21 : SEM image of Optimized Formulation (F3) 
 
 
 
                                      Figure-22  : SEM image of optimized Formulation (F7) 
Inference 
 SEM picture shows the formation of Spherical Nanoparticles. 
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PARTICLE SIZE DISTRIBUTION BY MALVERN ZETA SIZER:
Figure-23 :Size distribution of optimized formulation F3 
Inference: The average particle size of Nystatin loaded Nanosponge is 231.1 nm and the 
poly dispersity index was found to be 1.000 
RESULTS AND DISCUSSION 
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Figure-24: Size distribution of optimized formulation F7 
Inference 
The average particle size of NystatinNanosponge F7 was 370.3nm and the 
polydispersity index was found to be 1.000 
RESULTS AND DISCUSSION 
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Table-19  : in-vitro drug release of pure drug and NystatinNanosponges (EC) 
Time in 
Hours 
PURE 
DRUG 
F1 F2 F3 F4 F5 
0 0 0 0 0 0 0 
1 0.61 1.7 1.74 2.84 2.07 1.03 
2 0.66 3.49 2.54 5.06 3.57 1.8 
3 0.84 4.45 3.61 8.41 5.29 2.51 
4 1 5.68 4.87 10.69 6.32 3.83 
5 1.17 6.82 4.97 13.06 7.71 4.31 
6 1.31 7.71 5.71 14.55 8.51 4.96 
7 1.58 9.28 6.95 16.75 10.04 5.79 
8 1.74 11.12 8.47 18.6 10.66 6.39 
9 1.8 12.38 9.07 19.71 11.09 7.37 
10 1.91 14.03 9.8 22.51 11.61 8.73 
11 2 16.84 10.79 24.44 12.81 9.82 
23 2.54 17.97 17.52 31.92 17.8 13.75 
24 2.63 20.11 23.3 36.28 20.46 16.68 
 
 
 
Figure-25:  in- vitro drug release of Nystatin Nanosponge(EC) and pure drug 
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Table-20: in-vitro drug release of pure drug and Nystatin Nanosponge (PMMA) 
Time in 
Hours 
PURE 
DRUG 
F6 F7 F8 F9 F10 
0 0 0 0 0 0 0 
1 0.61 1.23 4.14 1.27 1.63 1.69 
2 0.66 2.47 7.3 2 2.94 3.34 
3 0.84 3.8 10.16 2.81 4.06 4.97 
4 1 5.75 14.13 3.63 5.24 6.83 
5 1.17 6.65 15.94 4.76 6.47 8.08 
6 1.31 7.72 18.69 5.25 7.67 9.46 
7 1.58 9.85 20.72 6.15 8.65 11.5 
8 1.74 10.38 232 7.16 9.35 12.62 
9 1.8 12.23 27.06 7.49 10.53 14.73 
10 1.91 12.96 29.16 8.54 11.49 15.8 
11 2 13.79 35.58 9.05 12.47 21.85 
23 2.54 20.02 41.45 14.5 17.61 23.46 
24 2.63 22.71 45.66 15.35 19.11 25.26 
 
 
Figure-26 : in -vitro drug release of Nystatin Nanosponge (PMMA) with pure drug. 
Inference 
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The in-vitro release of the formulations was observed to be between15.53% to 45.66 
%The results shown that the increase in polymer concentration increase the drug release and 
then it is decreased as described by Dr Prathima Srinivas et al
30
. From the  result it was 
observed that the  formulations  F3and  F7Showed sustained release of drug. 
Table-21 : in-vitro drug release of pure drug, marketed sample (Nistatina cream) and 
Nystatin Nanosponge gel (EC and PMMA) G1 and G2 
Time in hours Pure drug 
Marketed 
cream 
Nanosponge Gel 
G1 
Nanosponge Gel 
G2 
0 0 0 0 0 
1 0.61 0.9 2.73 3.18 
2 0.66 1.2 5.18 5.36 
3 0.84 1.39 7.39 7.28 
4 1 1.51 8.62 9.73 
5 1.17 1.64 9.28 10.73 
6 1.31 1.79 11.03 11.37 
7 1.58 1.92 12.66 14.3 
8 1.74 2.11 14.24 16.06 
9 1.8 2.33 15.05 17.28 
10 1.91 2.5 15.81 18.17 
11 2 2.66 16.59 19.1 
23 2.54 2.87 21.75 26.04 
24 2.63 3.01 23.15 28.88 
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Figure-27: in-vitro drug release of Pure drug, Marketed sample (Nistatina cream) 
and Nystatin Nanosponge gel G1 and G2 
Inference 
 The in–vitro release of the Gel formulation of F3 and F7 was compared with 
marketed sample of Nystatin cream, and the release of Nanosponge gel (G1 and G2) was 
23.15% and 28.88% respectively.  
The release of gel was increased due to the decreased particle size and increased 
surface area as described by Rawia M. Khalil et al
28
. 
 
                             Figure-28 :   Diffusion Study By Dialysis Bag method 
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KINETICS OFDRUG RELEASE 
Thein-vitroreleasedatawasappliedtovariouskineticmodelstopredictthemechanism 
ofdrugreleaseoftheNanospongeformulations. 
Table -22   : Release kinetics of  NystatinNanosponge Optimized formulation F3 
Time in 
Hours 
%cum 
drug 
release 
% drug 
remaining 
Log%cum 
drug 
remaining 
Square 
root of 
time 
Log 
time 
Cube root 
of  % 
drug 
remaining 
Log %cum 
drug release 
0 0 100 2 0   4.641589   
1 2.84 97.16 1.98748 1 0 4.597225 0.453318 
2 5.06 94.94 1.97744 1.41421 0.30102 4.561941 0.704151 
3 8.41 91.59 1.96184 1.73205 0.47712 4.507641 0.924796 
4 10.69 89.31 1.95090 2 0.60205 4.469922 1.028978 
5 13.06 86.94 1.93921 2.23606 0.69897 4.430028 1.115943 
6 14.55 85.45 1.93171 2.44949 0.77815 4.404575 1.162863 
7 16.75 83.25 1.92038 2.64575 0.84509 4.366445 1.224015 
8 18.6 81.4 1.91064 2.82842 0.90308 4.333859 1.269513 
9 19.71 80.29 1.90466 3 0.95424 4.314069 1.294687 
10 22.51 77.49 1.88924 3.16227 1 4.263326 1.352375 
11 24.44 75.56 1.87829 3.31662 1.04139 4.227633 1.388101 
23 31.92 68.08 1.83302 4.79583 1.36172 4.083255 1.504063 
24 36.28 63.72 1.80427 4.89897 1.38021 3.994158 1.559667 
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       Figure-29: Zero OrderKineticsof F3 
 
 
 
                                                         Figure-30  :FirstOrderKinetics of F3 
 
 
y = 1.3752x + 4.9585 
R² = 0.9149 
0
10
20
30
40
0 10 20 30
%
cu
m
u
la
ti
ve
 d
ru
g 
re
le
as
e
 
Time in hours 
Zero order release 
Kinetics 
y = -0.0075x + 1.9811 
R² = 0.9448 
1.75
1.8
1.85
1.9
1.95
2
2.05
0 10 20 30
lo
g%
cu
m
u
la
ti
ve
 d
ru
g 
re
m
ai
n
in
g 
Time in hours 
First order relaese 
Kinetics 
RESULTS AND DISCUSSION 
Department of Pharmaceutics, Madras Medical College Page 93 
 
 
                               
Figure-31: Higuchi ReleaseKinetic of F3 
 
 
 
 
Figure-32:HixonCrowellReleaseKinetics of F3 
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                                   Figure-33:KorsmeyerPeppas Release Kinetics of F3 
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                                                  Table-23 :  Release kinetics of F3  
 
S.No. 
 
Release 
Kinetics 
 
X-
axis 
 
Y-axis 
 
Slope 
 
Intercept 
 
R
2 
 
Linear 
Equation 
 
1. 
Zero order 
equation 
Time  
in 
hours 
Cumulative 
%drug 
release 
 
1.375 
 
4.958 
 
0.914 
 
y=1.375x+4.958 
R²=0.914 
 
 
2. 
First order 
equation 
Time 
in 
hours 
Log% 
cumulative 
drug 
release 
 
-0.007 
 
1.981 
 
0.944 
 
y=-0.007x+1.981 
R² = 0.944 
 
 
3. 
Higuchi 
release 
kinetic 
Squar
e root 
of 
time 
Cumulative 
%drug 
release 
 
7.803 
 
-3.717 
 
0.973 
 
y=7.803x-3.717 
R² = 0.973 
 
 
4. 
Hixon 
Crowell 
equation 
Time 
in 
hours 
Cube root 
of % drug 
release 
 
-0.024 
 
4.570 
 
0.935 
 
y=-0.024x+4.570 
R² = 0.935 
 
 
5 
 
Korsmeyer 
Peppas 
equation 
 
Log 
time 
Log % 
cumulative 
drug release 
 
0.793 
 
0.521 
 
0.975 
 
y=0.793x+0.521 
R² = 0.975 
 
Inference 
   Formulation F3 followed first- kinetics and their R2 value 0.944 indicating the 
release to be dose dependent. 
   The drug release was proportional to the square root of time indicating 
that Nystatin release from Nanosponge was diffusion controlled. 
       The n value for the korsmeyer- peppas for formulation F3 was found to be 
0.793. So the formulation F3  non-Fickian type  mechanism. 
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       The Drug release pattern from Formulation F3 follows First order release, 
Higuchi model and Non-fickian transport. 
Table-24 : Release kinetics of  Nystatin Nanosponge Optimized formulation F7 
Time in 
Hours 
%cum 
drug 
release 
% drug 
remaining 
Log% 
cum 
drug 
remain
ing 
Square 
root of 
time 
Log 
time 
Cube root 
of  % 
drug 
remaining 
Log %cum 
drug release 
0 0 100 2 0   4.641588   
1 4.14 95.86 1.981637 1 0 4.57663 0.617 
2 7.3 92.7 1.96708 1.414214 0.30103 4.525777 0.863323 
3 10.16 89.84 1.95347 1.732051 0.477121 4.478747 1.006894 
4 14.13 85.87 1.933841 2 0.60206 4.411779 1.150142 
5 15.94 84.06 1.924589 2.236068 0.69897 4.380561 1.202488 
6 18.69 81.31 1.910144 2.44949 0.778151 4.332261 1.271609 
7 20.72 79.28 1.899164 2.645751 0.845098 4.295903 1.31639 
8 23.2 76.8 1.885361 2.828427 0.90309 4.250634 1.365488 
9 27.06 72.94 1.862966 3 0.954243 4.178193 1.432328 
10 29.16 70.84 1.850279 3.162278 1 4.137704 1.464788 
11 35.58 64.42 1.809021 3.316625 1.041393 4.00873 1.551206 
23 41.45 58.55 1.767527 4.795832 1.361728 3.883073 1.617525 
24 45.66 54.34 1.73512 4.898979 1.380211 3.787679 1.659536 
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Figure-34: Zero OrderKineticsof F7 
 
 
 
Figure-35: First OrderKineticsof F7 
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             Figure-36:Higuchi Release kinetics of F7  
 
 
 
 
 
Figure-37:HixonCrowellReleaseKinetics of F7 
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Figure-38:KorsmeyerPeppas ReleaseKinetics of F7 
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Table-25:  Release kinetics of F7 
 
S.No. 
 
Release 
Kinetics 
 
X-axis 
 
Y-axis 
 
Slope 
 
Intercept 
 
R
2 
 
Linear 
Equation 
 
1. 
 
Zero order 
equation 
 
Time  
in 
hours 
Cumulative 
% drug 
release 
 
1.770 
 
6.651 
 
0.892 
 
y = 1.770x 
+ 6.651 
R² = 0.892  
 
 
2. 
 
First order 
equation 
 
Time 
in 
hours 
Log% 
cumulative 
drug 
release 
 
-0.010 
 
1.975 
 
0.929 
 
y = -0.010x + 
1.975 
R² = 0.929  
 
 
3. 
 
Higuchi 
release 
kinetic 
 
Square 
root of 
time 
Cumulative 
% drug 
release 
 
10.09 
 
-4.640 
 
0.958 
y = 10.09x 
- 4.640 
R² = 0.958  
 
 
4. 
 
Hixon 
Crowell 
equation 
 
Time 
in 
hours 
Cube root 
of % drug 
release 
 
-0.033 
 
4.548 
 
0.918 
y = -0.033x + 
4.548 
R² = 0.918  
 
 
5 
 
Korsmeyer 
Peppas 
equation 
 
Log 
time 
Log % 
cumulative 
drug 
release 
 
0.768 
 
0.659 
 
0.975 
y = 0.768x 
+ 0.659 
R² = 0.975  
 
Inference 
  Formulation F7 followed first- kinetics and their R2 value 0.929 indicating the 
release to be dose dependent. 
   The drug release was proportional to the square root of time indicating 
that Nystatin release from Nanosponge was diffusion controlled. 
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  The n value for the korsmeyer- peppas for formulation F7 was found to be 
0.768. So the formulation F7  non-Fickian type  mechanism. 
       The Drug release pattern from Formulation F7 follows First order release, 
Higuchi model and Non-fickian transport. 
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Table-26 : Release kinetics of  Nystatin Nanosponge Gel- G1 
Time in 
Hours 
%cum 
drug 
release 
% drug 
remaining 
Log% 
cum 
drug 
remain
ing 
Square 
root of 
time 
Log 
time 
Cube root 
of  % 
drug 
remaining 
Log %cum 
drug release 
0 0 100 2 0   4.641589   
1 2.73 97.27 1.987979 1 0 4.59896 0.436163 
2 5.18 94.82 1.9769 1.414214 0.30103 4.560018 0.71433 
3 7.39 92.61 1.966658 1.732051 0.477121 4.524312 0.868644 
4 8.62 91.38 1.960851 2 0.60206 4.504193 0.935507 
5 9.28 90.72 1.957703 2.236068 0.69897 4.493323 0.967548 
6 11.03 88.97 1.949244 2.44949 0.778151 4.464243 1.042576 
7 12.66 87.34 1.941213 2.645751 0.845098 4.436812 1.102434 
8 14.24 85.76 1.933285 2.828427 0.90309 4.409895 1.15351 
9 15.05 84.95 1.929163 3 0.954243 4.395967 1.177536 
10 15.81 84.19 1.925261 3.162278 1 4.382818 1.198932 
11 16.59 83.41 1.921218 3.316625 1.041393 4.369241 1.219846 
23 21.75 78.25 1.893484 4.795832 1.361728 4.277218 1.337459 
24 23.15 76.85 1.885644 4.898979 1.380211 4.251556 1.364551 
 
 
                                                        Figure-39:  Zero OrderKineticsof G1 
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                                                         Figure-40:  First orderKineticsof G1 
 
 
 
                                                   Figure-41: Higuchi Release kinetics of G1 
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                                         Figure-42: Hixon Crowell Release kinetics of G1 
 
 
 
                                 Figure-43   :KorsmeyerPeppas release kinetics oh G1. 
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                                                  Table-27 :  Release kinetics of  G1 
 
S.No. 
 
Release 
Kinetics 
 
X-axis 
 
Y-axis 
 
Slope 
 
Intercept 
 
R
2 
 
Linear 
Equation 
 
1. 
 
Zero order 
equation 
 
Time  
in 
hours 
Cumulative 
% drug 
release 
 
0.854 
 
4.780 
 
0.871 
 
y =0.854x+4.780 
     R² = 0.871  
 
 
2. 
 
First order 
equation 
 
Time 
in 
hours 
Log% 
cumulative 
drug 
release 
 
-0.004 
 
1.979 
 
0.896 
 
y = -0.004x + 1.979 
R² = 0.896  
 
 
3. 
 
Higuchi 
release 
kinetic 
 
Square 
root of 
time 
Cumulative 
% drug 
release 
 
4.991 
 
-0.972 
 
0.981 
 
y =4.991x -0.972 
       R² = 0.981  
 
 
4. 
 
Hixon 
Crowell 
equation 
 
Time 
in 
hours 
Cube root 
of % drug 
release 
 
-0.014 
 
4.568 
 
0.888 
 
y = -0.014x + 4.568 
R² = 0.888  
 
 
5 
 
Korsmeyer 
Peppas 
equation 
 
Log 
time 
Log % 
cumulative 
drug release 
 
0.812 
 
0.365 
 
0.882 
 
y =0.812x+0.365 
       R² = 0.882  
 
Inference 
  Formulation G1 followed first- kinetics and their R2 value 0.896 indicating the 
release to be dose dependent. 
   The drug release was proportional to the square root of time indicating 
that Nystatin release from Nanosponge gel was diffusion controlled. 
       The n value for the korsmeyer- peppas for formulation G1 was found to be 0.812. 
So the formulation G1  non-Fickian type  mechanism. 
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       The Drug release pattern from Formulation G1 follows First order release, 
Higuchi model and Non-fickian transport. 
                                    Table-28 : Release kinetics of  Nystatin Nanosponge Gel-G2 
Time in 
Hours 
%cum 
drug 
release 
% drug 
remaining 
Log% 
cum 
drug 
remain
ing 
Square 
root of 
time 
Log 
time 
Cube root 
of  % 
drug 
remaining 
Log %cum 
drug release 
0 0 100 2 0   4.641588   
1 3.18 96.82 1.985965 1 0 4.591857 0.502427 
2 5.36 94.64 1.976075 1.414214 0.30103 4.557131 0.729165 
3 7.28 92.72 1.967173 1.732051 0.477121 4.526103 0.862131 
4 9.73 90.27 1.955543 2 0.60206 4.485881 0.988113 
5 10.73 89.27 1.950706 2.236068 0.69897 4.469255 1.0306 
6 11.37 88.63 1.947581 2.44949 0.778151 4.458549 1.05576 
7 14.3 85.7 1.932981 2.645751 0.845098 4.408866 1.155336 
8 16.06 83.94 1.923969 2.828427 0.90309 4.378476 1.205746 
9 17.28 82.72 1.917611 3 0.954243 4.35716 1.237544 
10 18.17 81.83 1.912913 3.162278 1 4.341477 1.259355 
11 19.1 80.9 1.907949 3.316625 1.041393 4.324967 1.281033 
23 26.04 73.96 1.868997 4.795832 1.361728 4.197579 1.415641 
24 28.88 71.12 1.851992 4.898979 1.380211 4.143149 1.460597 
 
 
                                                     Figure-44: Zero order kinetics of G2 
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Figure-45 :First order kinetics of G2 
 
 
 
Figure-46: Higuchi release kinetics of G2 
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Figure-47 :Hixon Crowell release kinetics of G2 
 
 
 
 
Figure-48:KorsmeyerPeppas release kinetics of G2 
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                                                             Table-29   :  Release kinetics of  G2 
 
 
S.No. 
 
Release 
Kinetics 
 
X-axis 
 
Y-axis 
 
Slope 
 
Intercept 
 
R
2 
 
Linear 
Equation 
 
1. 
 
Zero order 
equation 
 
Time  
in 
hours 
Cumulative 
% drug 
release 
 
1.074 
 
4.715 
 
0.908 
 
y =1.074x+4.715 
      R² = 0.908  
 
 
2. 
 
First order 
equation 
 
Time 
in 
hours 
Log% 
cumulative 
drug 
release 
 
-0.005 
 
1.980 
 
0.934 
 
y = -0.005x +1.980 
R² = 0.934  
 
 
3. 
 
Higuchi 
release 
kinetic 
 
Square 
root of 
time 
Cumulative 
% drug 
release 
 
6.143 
 
-2.177 
 
0.980 
 
y =6.143x -2.177 
       R² = 0.980  
 
 
4. 
 
Hixon 
Crowell 
equation 
 
Time 
in 
hours 
Cube root 
of % drug 
release 
 
-0.018 
 
4.571 
 
0.926 
 
y = -0.018x + 4.571 
R² = 0.926  
 
 
5 
 
KorsmeyerP
eppas 
equation 
 
Log 
time 
Log % 
cumulative 
drug release 
 
0.857 
 
0.379 
 
0.89 
 
y =0.857x+0.379 
        R² = 0.89  
 
 Inference 
  Formulation G2followed first- kinetics and their R2 value 0.934 indicating the 
release to be dose dependent. 
   The drug release was proportional to the square root of time indicating 
that Nystatin release from Nanosponge gel was diffusion controlled. 
       The n value for the korsmeyer- peppas for formulation G2 was found to be 0.857. 
So the formulation G2  non-Fickian type  mechanism. 
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       The Drug release pattern from Formulation G2 follows First order release, 
Higuchi model and Non-fickian transport. 
 
Table-30: Drug Release Kinetics for optimized Formulation and their Gel 
The regression coefficient (R
2
)was determined using the drug release data. The results 
were shown in the Table   : 
FORMULATION 
CODE 
ZERO 
ORDER 
FIRST 
ORDER 
HIGUCHI 
MODEL 
HIXSON 
CROWELL 
KORSMEYER 
PEPPAS 
R
2 
R
2
 R
2
 R
2
 R
2
 n 
F3 0.914 0.944 0.973 0.935 0.975 0.793 
F7 0.892 0.929 0.958 0.918 0.975 0.768 
G1 0.871 0.896 0.981 0.888 0.882 0.812 
G2 0.908 0.934 0.980 0.926 0.89 0.857 
Inference 
 All the formulations followed first- order kinetics and their R2 value lied between 0.896 
to 0.944  indicating the release to be dose dependent. 
 The drug release was proportional to the square root of time indicating that 
Nystatin release from Nanosponge and Gel was diffusion controlled. 
       The n value for the korsmeyer- peppas for formulation F3, F7,G1 and G2 was found 
to be lied between 0.768   to 0.857.. So the formulation F3, F7,G1 and G2  follows non-
Fickian type  mechanism. 
       The Drug release pattern from Nystatin loaded Nanosponge follows First order 
release, Higuchi model and Non-fickian transport. 
        The release of Nystatin Nanosponge gel occurs through the First order, Higuchi 
model and non – fickian diffusion mechanism. 
 
 
RESULTS AND DISCUSSION 
 
Department of Pharmaceutics, Madras Medical College Page  
 
111 
ANTI FUNGAL ACTIVITY 
 
 
Figure-49 : After inoculation,0 min growth. 
 
Figure-50: After 48 hrs of inoculation of G1 
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Figure-51:After 48hrs of inoculation for G2 
 
 
Figure-52: After 48 hrs of inoculation for Marketed sample (Nystatin cream), G1 and G2 
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Evaluation of Gel  
Table-31: Evaluation of Gel  
S.No. Code 
Physical 
appearance 
%Drug 
content 
Viscosity  (cps) pH 
%Drug 
release 
1. G1 Good 91.10 2.939 x 10
6 4.89 25.15 
2. G2 Good 94.55 2.853 x 10
6 4.92 28.88 
 
Antimicrobial activity of NystatinNanosponge Gel 
Table-32: Antimicrobial activity of NystatinNanosponge Gel 
S.No. Formulation code 
Anti fungal activity(Zone of inhibition) in 
mm 
1. Control 0 
2. G1 18±0.8164 
3. G2 19.33±1.2472 
4. Marketed sample 11.667±0.4714 
 
 
Figure-53: Antifungal activity. 
Inference  
  The antifungal activity for   Nystatin Nanosponge Gel  G2 Zone of Inhibition 
was 19.33mm, for G1 Zone of Inhibition was 18mm and the zone of inhibition obtained 
for Marketed sample was 11.667mm. The antifungal activity of the Nanosponge gel 
showed enhancement of Nystatin antifungal effect. 
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 The purpose of this research was to prepare Nystatin loaded 
Nanosponge gel for Sustained release of drug, increase the drug 
solubility, increase the drug permeability, to reduce the dosing 
frequency and side effects. 
 
 The FTIR studies proved that there were no interaction between the 
drug and Polymers. 
 
 Homogenization technique followed by centrifugation was employed  to 
prepare Nanosponge using various polymers. 
 
 The formulation were prepared using different Polymers 
(Ethylcellulose and Polymethyl methacrylate) in different ratios 
(Drug:Polymer–1:1,1:2,1:3,1:4 and1:5,) Using dichloromethane as cross 
linker as well as solvent. 
 
 
 The formulations were characterized for drug entrapment efficiency. 
The entrapment efficiency of the formulations was observed to be 
between 97.85 to 99.21. The highest entrapment efficiency was 
observed with 99.21 and 98.94 for the formulations  F3 and F7. 
 
 The formulations were characterized for drug content. The Drug 
content of the formulations was observed to be between 82.90 to 95.71.  
 
 
 The particle size analysis done by Malvern Zeta sizer showed that the 
average particle size of Nystatin loaded Nanosponge F3 and F7 was 
231.1 nm and 370.3 nm respectively. 
 
 The SEM analysis of Nanosponge shows the spherical  surface of the 
particles. 
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 The in-vitro release of Nystatin Nanopsonge optimized formulation 
F3wasfound tobe 36.28% andF7 was 45.66 % at theend of 24 hours. 
 The drug content of the Gel G1 and G2  was found to be 25.15% and 
28.88 %  respectively. 
 The in-vitro release of Nystatin Nanosponge Gel formulation 
G1wasfound tobe 23.15% andG2 was 28.88 % at theend of 24  hours. 
 The pH of the gels G1and G2 was found to be 4.89 and 4.92 
respectively. 
 The Viscosity of the gels G1 and G2 was found to be 2.939x 106 cps 
and 2.853x 10
6 
cps respectively. 
 Anti-fungal activity  of Nystatin Nanosponge Gel G2 showed highest 
zone of inhibition followed by gel G1 and Marketed Sample as 
Marzouk M . A. et al describes the increased zone of inhibition 
45
. 
 It was concluded that the Nystatin loaded Nanosponge Gel may have 
increased the solubility, drug release and Antifungal activity(Increase in 
Zone of Inhibition), and provide  Sus ta ined ef fec t .  
 
FUTURE SCOPE 
 To perform in-vivo study. 
 To perform ex-vivo study. 
 To determine the dosage regimen of the formulation. 
 To do effect of Anti fungal activity to other species. 
 To develop the Oral dosage form. 
 To carry out the IVIVC. 
 To perform Toxicity studies. 
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